WO2003030872A2 - Compositions having a combination of particles for immediate release and for controlled release - Google Patents

Compositions having a combination of particles for immediate release and for controlled release Download PDF

Info

Publication number
WO2003030872A2
WO2003030872A2 PCT/US2002/032314 US0232314W WO03030872A2 WO 2003030872 A2 WO2003030872 A2 WO 2003030872A2 US 0232314 W US0232314 W US 0232314W WO 03030872 A2 WO03030872 A2 WO 03030872A2
Authority
WO
WIPO (PCT)
Prior art keywords
active agent
less
composition
particles
nanoparticulate
Prior art date
Application number
PCT/US2002/032314
Other languages
French (fr)
Other versions
WO2003030872A3 (en
Inventor
Eugene R. Cooper
Stephen B. Ruddy
Original Assignee
Elan Pharma International Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd. filed Critical Elan Pharma International Ltd.
Priority to AU2002334939A priority Critical patent/AU2002334939A1/en
Priority to CA2463495A priority patent/CA2463495C/en
Priority to JP2003533905A priority patent/JP2005508939A/en
Priority to DK02800993T priority patent/DK1443912T3/en
Priority to EP02800993A priority patent/EP1443912B1/en
Priority to DE60222160T priority patent/DE60222160T2/en
Publication of WO2003030872A2 publication Critical patent/WO2003030872A2/en
Publication of WO2003030872A3 publication Critical patent/WO2003030872A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • the present invention relates to compositions exhibiting a combination of immediate release and controlled release characteristics.
  • the compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one poorly soluble active ingredient having a microparticulate particle size.
  • Nanoparticulate compositions are particles consisting of a poorly soluble active agent having adsorbed onto the surface thereof a non-crosslinked surface stabilizer.
  • the '684 patent also describes methods of making such nanoparticulate compositions. Nanoparticulate compositions are desirable because with a decrease in particle size, and a consequent increase in surface area, a composition is rapidly dissolved and absorbed following administration. Methods of making such compositions are described in U.S. Patent Nos. 5,518,187 and 5,862,999, both for "Method of Grinding Pharmaceutical Substances," U.S. Patent No. 5,718,388, for "Continuous Method of Grinding Pharmaceutical Substances;” and U.S. Patent No. 5,510,118 for "Process of Preparing Therapeutic Compositions Containing Nanoparticles.”
  • Nanoparticulate compositions are also described in, for example, U.S. Patent Nos. 5,298,262 for "Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" 5,302,401 for “Method to Reduce Particle Size Growth During Lyophilization;” 5,318,767 for “X-Ray Contrast Compositions Useful in Medical Imaging;” 5,326,552 for “Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;” 5,328,404 for “Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;” 5,336,507 for “Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;” 5,340,564 for “Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;” 5,346,702 for "Use of Non-Ionic Cloud Point Mod
  • Amorphous small particle compositions are described in, for example, U.S. Patent Nos. 4,783,484 for "Particulate Composition and Use Thereof as Antimicrobial Agent," 4,826,689 for “Method for Making Uniformly Sized Particles from Water- Insoluble Organic Compounds," 4,997,454 for “Method for Making Uniformly-Sized Particles From Insoluble Compounds,” 5,741,522 for "Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods," and 5,776,496, for "Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter.
  • “rapidly disintegrating" dosage forms rely on the composition of the drug matrix to effect the rapid release of the component active agent particles, rather than the particle size of the component active agent particles.
  • Cima Labs markets OraSolv ® , which is an effervescent direct compression tablet having an oral dissolution time of five to thirty seconds, and DuraSolv ® , which is a direct compression tablet having a taste-masked active agent and an oral dissolution time of 15 to 45 seconds.
  • the microparticle core has a pharmaceutical agent and one or more sweet-tasting compounds having a negative heat of solution selected from mannitol, sorbitol, a mixture of an artificial sweetener and menthol, a mixture of sugar and menthol, and methyl salicylate.
  • the microparticle core is coated, at least partially, with a material that retards dissolution in the mouth and masks the taste of the pharmaceutical agent.
  • the microparticles are then compressed to form a tablet. Other excipients can also be added to the tablet formulation.
  • WO 98/46215 for "Rapidly Dissolving Robust Dosage Form," assigned to Cima Labs, is directed to a hard, compressed, fast melt formulation having an active ingredient and a matrix of at least a non-direct compression filler and lubricant.
  • a non- direct compression filler is typically not free-flowing, in contrast to a direct compression (DC grade) filler, and usually requires additionally processing to form free-flowing granules.
  • Cima also has U.S. patents and international patent applications directed to effervescent dosage forms (U.S. Patent Nos. 5,503,846, 5,223,264, and 5,178,878) and tableting aids for rapidly dissolving dosage forms (U.S. Patent Nos. 5,401,513 and 5,219,574), and rapidly dissolving dosage forms for water soluble drugs (WO 98/14179 for "Taste-Masked Microcapsule Composition and Methods of Manufacture").
  • R.P. Scherer markets Zydis ® which is a freeze-dried tablet having an oral dissolution time of 2 to 5 seconds. Lyophilized tablets are costly to manufacture and difficult to package because of the tablets sensitivity to moisture and temperature.
  • U.S. Patent No. 4,642,903 (R.P. Scherer Corp.) refers to a fast melt dosage formulation prepared by dispersing a gas throughout a solution or suspension to be freeze-dried.
  • U.S. Patent No. 5,188,825 (R.P. Scherer Corp.) refers to freeze-dried dosage forms prepared by bonding or complexing a water-soluble active agent to or with an ion exchange resin to form a substantially water insoluble complex, which is then mixed with an appropriate carrier and freeze dried.
  • U.S. Patent No. 5,631,023 refers to freeze-dried drug dosage forms made by adding xanthan gum to a suspension of gelatin and active agent.
  • U.S. Patent No. 5,827,541 discloses a process for preparing solid pharmaceutical dosage forms of hydrophobic substances. The process involves freeze-drying a dispersion containing a hydrophobic active ingredient and a surfactant in a non-aqueous phase and a carrier material in an aqueous phase.
  • Eurand America, Inc. has U.S. patents directed to a rapidly dissolving effervescent composition having a mixture of sodium bicarbonate, citric acid, and ethylcellulose (U.S. Patent Nos. 5,639,475 and 5,709,886).
  • Schering Corporation has technology relating to buccal tablets having an active agent, an excipient (which can be a surfactant) or at least one of sucrose, lactose, or sorbitol, and either magnesium stearate or sodium dodecyl sulfate (U.S. Patent Nos. 5,112,616 and 5,073,374).
  • an excipient which can be a surfactant
  • sucrose lactose
  • sorbitol sorbitol
  • magnesium stearate or sodium dodecyl sulfate U.S. Patent Nos. 5,112,616 and 5,073,374.
  • Controlled release refers to the release of an agent such as a drug from a composition or dosage form in which the agent is released according to a desired profile over an extended period of time.
  • Controlled release profiles include, for example, sustained release, prolonged release, pulsatile release, and delayed release profiles.
  • immediate release compositions controlled release compositions allow delivery of an agent to a subject over an extended period of time according to a predetermined profile.
  • Such release rates can provide therapeutically effective levels of agent for an extended period of time and thereby provide a longer period of pharmacologic or diagnostic response as compared to conventional rapid release dosage forms.
  • Such longer periods of response provide for many inherent benefits that are not achieved with the corresponding short acting, immediate release preparations.
  • controlled release formulations are often highly preferred over conventional short-acting formulations.
  • Controlled release pharmaceutical compositions and dosage forms are designed to improve the delivery profile of agents, such as drugs, medicaments, active agents, diagnostic agents, or any substance to be internally administered to an animal, including humans.
  • a controlled release composition is typically used to improve the effects of administered substances by optimizing the kinetics of delivery, thereby increasing bioavailability, convenience, and patient compliance, as well as minimizing side effects associated with inappropriate immediate release rates such as a high initial release rate and, if undesired, uneven blood or tissue levels.
  • compositions providing for controlled release of an active compound provide various methods of extending the release of a drug following administration.
  • Exemplary controlled release formulations known in the art include specially coated pellets, microparticles, implants, tablets, minitabs, and capsules in which a controlled release of a drug is brought about, for example, through selective breakdown of the coating of the preparation, through release through the coating, through compounding with a special matrix to affect the release of a drug, or through a combination of these techniques.
  • Some controlled release formulations provide for pulsatile release of a single dose of an active compound at predetermined periods after administration.
  • U.S. Patent No. 5,110,605 to Acharya et al. refers to a calcium polycarbophil- alginate controlled release composition.
  • U.S. Patent No. 5,215,758 to Krishnamurthy et al. refers to a controlled release suppository composition of sodium alginate and calcium salt.
  • U.S. Patent No. 5,811,388 to Friend et al. refers to a solid alginate-based formulation including alginate, a water-swellable polymer, and a digestible hydrocarbon derivative for providing controlled release of orally administered compounds.
  • WO 91/13612 refers to the sustained release of pharmaceuticals using compositions in which the drug is complexed with an ion-exchange resin.
  • biodegradable polymers such as polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, etc.
  • U.S. Patent No. 5,811,404 to De Frees et al. refers to the use of liposomes having prolonged circulation half-lives to provide for the sustained release of drug compositions.
  • WO 00/18374 for “Controlled Release Nanoparticulate Compositions,” describes controlled release formulations comprising nanoparticulate active agents.
  • compositions of poorly soluble drugs having a combination of immediate release and controlled release characteristics There is a need in the art for compositions of poorly soluble drugs having a combination of immediate release and controlled release characteristics.
  • the present invention satisfies this need.
  • This invention is directed to the surprising and unexpected discovery of formulations of poorly soluble active agents having a combination of immediate active agent release and controlled active agent release characteristics.
  • the formulations comprise a combination of very small active agent particles, i.e., nanoparticulate active agent particles, in combination with larger active agent particles, i.e., micronized active agent particles, which enable obtaining the simultaneous presentation of immediate- release (TR) and controlled-release (CR) active agent components.
  • TR immediate- release
  • CR controlled-release
  • nanoparticulate active agent particles representing the IR component
  • micronized active agent particles representing the CR component
  • afford slower in vivo dissolution owing to a comparatively large particle size and small attendant specific surface.
  • compositions can comprise a mixture of nanoparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate, and the compositions can comprise a mixture of microparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate.
  • compositions of the invention are highly unexpected, particularly since the controlled delivery of active agents has traditionally been achieved through employment of rate-controlling membranes, swellable and erodible polymers, and ion-exchange resins, rather than solely through the particle size of the active agent component of the dosage form.
  • a method of preparing formulations having a combination of IR and CR characteristics comprises: (1) forming a composition comprising particles of at least one nanoparticulate active agent to be administered and at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles; (2), adding at least one microparticulate active agent, which can be the same or different from the active agent of (1), and (3) forming a dosage form of the mixture of (1) and (2) for administration. Additional pharmaceutically acceptable excipients can also be added to the composition for administration.
  • Yet another aspect of the present invention provides a method of treating a mammal, including a human, with a composition of the invention.
  • FIGURE 1 Shows a simulation, using a mathematical model, of pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing an active agent having a single defined particle size
  • FIGURE 2 Shows a simulation, using a mathematical model, of pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing mixtures of different sizes of particles;
  • FIGURE 3 Shows a simulation, using a mathematical model, of pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing mixtures of different sizes of particles.
  • This invention is directed to the surprising and unexpected discovery of new compositions exhibiting a combination of IR and CR characteristics.
  • the compositions do not require the presence of an additional ingredient, such as a rate controlling polymer or membrane, a swellable or erodible polymer, or ion-exchange resin, to obtain the CR characteristics.
  • the IR and CR characteristics are obtained using precisely calibrated particle sizes for the one or more active agents. Smaller particle sizes result in IR profiles and larger particle sizes result in CR profiles.
  • compositions of the invention comprise: (1) particles of at least one poorly soluble nanoparticulate active agent; (2) at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles; and (3) at least one poorly soluble microparticulate active agent, which can be the same as or different from the active agent of (1).
  • the surface stabilizer functions to stabilize the nanoparticulate active agent by preventing agglomeration and particle size growth.
  • nanoparticulate active agent compositions which can comprise mechanical grinding, precipitation, homogenization, or any other suitable size reduction process, are known in the art and are described in, for example, the '684 patent and other prior art references disclosed in the "Background of the Invention.”
  • the nanoparticulate and microparticulate active agent particles can be in a crystalline form, semi-crystalline form, amorphous form, semi-amorphous form, or a combination thereof.
  • compositions can be formulated for administration to humans and animals via any conventional means, including but not limited to orally, rectally, parenterally (intravenous, intramuscular, or subcutaneous), intracisternally, pulmonary, intravaginally, intraperitoneally, locally (powders, ointments or drops), ocularly, aurally, or as a buccal or nasal spray.
  • the present invention also encompasses the compositions of the invention formulated together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
  • the compositions can be formulated for parenteral injection, oral administration in solid or liquid form, rectal or topical administration, ocular or aural administration, and the like.
  • the IR component results in rapid dissolution of the poorly soluble active agent in the oral cavity as a result of the nanoparticulate size of the drug. Further, the opportunity for buccal absorption of the poorly soluble active ingredient is enhanced with the present invention. Yet another advantage of the nanoparticulate IR component is that the use of nanoparticulate active agent particles eliminates or minimizes the feeling of grittiness found with prior art IR oral formulations of poorly soluble active agents.
  • One advantage typically associated with IR dosage forms is a reduction of the time lag between administration of a dose and the physical presentation of the active ingredient. This lag time is usually associated with the break up of the dosage form and the distribution of the active ingredient thereafter.
  • Another advantage of oral JJR. dosage forms is that the rapid presentation of the active agent in the mouth upon administration may facilitate buccal absorption of the active ingredient directly into the blood stream, thus reducing the first pass effect of the liver on the overall bioavailability of active ingredient from a unit dose.
  • This second advantage is dramatically enhanced for the IR formulations of the invention, as the nanoparticulate size of the active agent enables rapid dissolution in the oral cavity.
  • controlled release means the release of an active agent such as a drug from a composition or dosage form in which the agent is released according to a desired profile over an extended period of time, such as from about 2 to about 24 hours or longer. Release over a longer time period is also contemplated as a "controlled release" dosage form of the present invention.
  • An exemplary formulation is graphically illustrated below:
  • both of the IR and CR components are incorporated in a solid, rapidly disintegrating or "waterless tablet” matrix intended for oral administration.
  • the IR and CR components are combined in a pharmaceutically acceptable tablet intended for oral administration.
  • the IR and CR components are combined in a pharmaceutically acceptable hard gelatin capsule intended for oral administration.
  • the IR and CR components are combined in a pharmaceutically acceptable soft gelatin capsule intended for oral administration.
  • This dosage form comprises solubilized drag and microparticulate drug particles, in which the solubilized drug functions as the IR component and the microparticulate drug particles function as the CR component of the dosage form.
  • This variation differs from the other dosage forms described herein in that it does not require the presence of "particulate" nanoparticulate drug particles.
  • the IR and CR components are combined in a pharmaceutically acceptable lozenge or troche intended for oral administration.
  • the IR and CR components are combined in a pharmaceutically acceptable sachet, powder, or "sprinkle" intended for oral administration.
  • Suitable dosage forms include, but are not limited to, suppositories for rectal or intravaginally use; injectables, including injectables for intravenous, intramuscular, or subcutaneous administration; aerosols for pulmonary or nasal administration; buccal dosage forms; dosage forms for local application, such as powders, ointments, or drops; ocular and aural dosage forms, and dosage forms for intracisternal and intraperitoneal administration.
  • compositions of the invention can be combined in any pharmaceutically acceptable dosage form, which is not limited to those specifically described above.
  • compositions of the invention comprise at least one poorly soluble therapeutic agent, diagnostic agent, or other active agent.
  • a therapeutic agent can be a drug or pharmaceutical and a diagnostic agent is typically a contrast agent, such as an x- ray contrast agent, or any other type of diagnostic material.
  • the invention can be practised with a wide variety of poorly soluble drugs or diagnostic agents.
  • the drug or diagnostic agent is preferably present in an essentially pure form, is poorly soluble, and is dispersible in at least one liquid medium.
  • “poorly soluble” it is meant that the drug or diagnostic agent has a solubility in a liquid dispersion medium of less than about 30 mg/ml, preferably less than about 10 mg/ml, and more preferably less than about 1 mg/ml.
  • a liquid dispersion medium can be, for example, water, aqueous salt solutions, oils such as safflower oil, and solvents such as ethanol, t-butanol, hexane, and glycol.
  • the poorly soluble active agent can be selected from a variety of known classes of drugs or diagnostic agents, including, for example, proteins, peptides, nucleotides, anti-obesity drugs, nutraceuticals, corticosteroids, elastase inhibitors, analgesics, anti- fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti- inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives (e.g., hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic
  • nutraceuticals and dietary supplements are disclosed, for example, in Roberts et al., Nutraceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and Healing Foods (American Nutraceutical Association, 2001), which is specifically incorporated by reference.
  • a nutraceutical or dietary supplement also known as phytochemicals or functional foods, is generally any one of a class of dietary supplements, vitamins, minerals, herbs, or healing foods that have medical or pharmaceutical effects on the body.
  • nutraceuticals or dietary supplements include, but are not limited to, folic acid, fatty acids (e.g., DHA and ARA), fruit and vegetable extracts, vitamin and mineral supplements, phosphatidylserine, lipoic acid, melatonin, glucosamine/chondroitin, Aloe Vera, Guggul, glutamine, amino acids (e.g., iso-leucine, leucine, lysine, methionine, phenylanine, threonine, tryptophan, and valine), green tea, lycopene, whole foods, food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flax seeds, fish and marine animal oils, and probiotics. Nutraceuticals and dietary supplements also include bio- engineered foods genetically engineered to have a desired property, also known as "pharmafoods.”
  • the active agents are commercially available and/or can be prepared by techniques known in the art.
  • the poorly soluble active ingredient may be present in any amount which is sufficient to elicit a therapeutic effect and, where applicable, may be present either substantially in the form of one optically pure enantiomer or as a mixture, racemic or otherwise, of enantiomers. 4.
  • Surface Stabilizers are commercially available and/or can be prepared by techniques known in the art.
  • the poorly soluble active ingredient may be present in any amount which is sufficient to elicit a therapeutic effect and, where applicable, may be present either substantially in the form of one optically pure enantiomer or as a mixture, racemic or otherwise, of enantiomers. 4.
  • Useful surface stabilizers which are known in the art and described, for example, in the '684 patent, are believed to include those which physically adhere to the surface of the active agent but do not chemically bond to or interact with the active agent.
  • the surface stabilizer is adsorbed on the surface of the nanoparticulate active agent in an amount sufficient to maintain an effective average particle size of less than about 1000 nm for the active agent.
  • the individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages. Two or more surface stabilizers can be employed in the compositions and methods of the invention.
  • Suitable surface stabilizers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Preferred surface stabilizers include nonionic and ionic surfactants, including anionic and cationic surfactants.
  • surface stabilizers include gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens ® such as e.g., Tween 20 ® and Tween 80 ® (ICI Speciality Chemicals)); polyethylene glycols (e.g., Carbowaxs 3550 ® and 934 ® (Union Carbide)), polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate,
  • useful surface stabilizers include sodium lauryl sulfate, dioctyl sodium sulfosuccinate, or a combination thereof.
  • useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-mefhylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
  • PMMTMABr polymethylmethacrylate
  • cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C 12 .
  • cationic lipids such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride,
  • Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990).
  • nonpolymeric primary stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR 1 R 2 R 3 R 4 (+) .
  • benzalkonium chloride a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary am
  • Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammonium chloride(Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbento
  • the IR characteristics of the dosage form are obtained by utilizing at least one nanoparticulate active agent having an effective average particle size of less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, or less than about 50 nm.
  • the CR characteristics of the dosage form are obtained by utilizing at least one microparticulate active agent having an effective average particle size of greater than about 1 micron and less than about 100 microns, less than about 90 microns, less than about 80 microns, less than about 70 microns, less than about 60 microns, less than about 50 microns, less than about 40 microns, less than about 30 microns, less than about 20 microns, less than about 10 microns, less than about 9 microns, less than about 8 microns, less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, less than about 3 microns, or less than about 2 microns.
  • compositions can comprise multiple populations of nanoparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate, i.e. a first population having an effective average particle size of less than about 1 micron, a second population having an effective average particle size of less than about 800 nm, a third population having an effective average particle size of less than about 500 nm, a fourth population having an effective average particle size of less than about 50 nm, etc., with each population corresponding to a specific release rate.
  • compositions can comprise multiple populations of microparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate, i.e. a first population having an effective average particle size of less than about 100 microns, a second population having an effective average particle size of less than about 60 microns, a third population having an effective average particle size of less than about 40 microns, a fourth population having an effective average particle size of less than about 20 microns, etc., with each population corresponding to a specific release rate.
  • Each population of particles in the composition both nanoparticulate and microparticulate, exhibits a baseline resolution of at least 50%, 60%, 70%, 80%, or 90%. This means that the heterogeneous population is characterized by a multi-modal particle size distribution, with a minimum baseline resolution of 50% relative to two adjacent peaks. 50% baseline resolution is defined as half the distance from the baseline of the distribution to the average height of two adjacent peaks.
  • the baseline resolution of at least 50% distinguishes the claimed invention from a conventional microparticulate composition having a mixture of particle sizes, as in such a conventional composition the particle sizes are randomly distributed and do not have a baseline resolution of at least 50% for two or more particle sizes.
  • particle size is determined on the basis of the weight average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and disk centrifugation.
  • an effective average particle size of less than about 1000 nm it is meant that at least 50% of the active agent particles have an average particle size of less than about 1000 nm, when measured by the above techniques.
  • an effective average particle size of less than about 100 microns it is meant that at least 50% of the active agent particles have an average particle size of less than about 100 microns, when measured by the above techniques.
  • at least 70% of the particles have an average particle size of less than the effective average, more preferably at least about 90% of the particles have an average particle size of less than the effective average.
  • compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.
  • excipients are known in the art.
  • filling agents are lactose monohydrate, lactose anhydrous, and various starches
  • binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel ® PHI 01 and Avicel ® PH102, microcrystalline cellulose, and silicifized microcrystalline cellulose (SMCC).
  • Suitable lubricants including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil ® 200; talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
  • sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
  • sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
  • flavoring agents are Magnasweet ® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
  • preservatives examples include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
  • Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing.
  • diluents include microcrystalline cellulose, such as Avicel ® PH101 and Avicel ® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose ® DCL21; dibasic calcium phosphate such as Emcompress ® ; mannitol; starch; sorbitol; sucrose; and glucose.
  • Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross- povidone, sodium starch glycolate, and mixtures thereof.
  • effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate.
  • Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
  • Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate.
  • only the acid component of the effervescent couple may be present.
  • the relative amount of at least one nanoparticulate active agent, one or more surface stabilizers, and at least one microparticulate active agent can vary widely.
  • the optimal amount of the surface stabilizers can depend, for example, upon the particular active agent selected, the hydrophilic lipophilic balance (HLB), melting point, and water solubility of the surface stabilizer, and the surface tension of water solutions of the stabilizer, etc.
  • the concentration of at least one nanoparticulate active agent can vary from about 99.5% to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined weight of the at least one active agent and at least one surface stabilizer, not including other excipients.
  • the concentration of at least one surface stabilizer can vary from about 0.5% to about 99.999%, from about 5% to about 99.9%, and from about 10% to about 99.5%, by weight, based on the total combined dry weight of at least one active agent and at least one surface stabilizer, not including other excipients.
  • the concentration of the microparticulate active agent can vary from about 5% to about 85%, by weight, based on the total combined weight of the nanoparticulate active agent, surface stabilizer, and microparticulate active agent, not including other excipients.
  • compositions of the Invention in another aspect of the invention there is provided a method of preparing formulations having combined CR and IR characteristics.
  • the method comprises: (1) forming a nanoparticulate composition comprising at least one nanoparticulate active agent to be administered and at least one surface stabilizer; (2) adding at least one microparticulate active agent, which is the same or different from the nanoparticulate active agent of (1), and (3) forming a suitable dosage form of the composition for administration.
  • Pharmaceutically acceptable excipients can also be added to the composition for administration.
  • nanoparticulate compositions which can comprise mechanical grinding, precipitation, homogenization, or any other suitable size reduction process, are known in the art and are described in, for example, the '684 patent.
  • Milling of aqueous active agent dispersions to obtain a nanoparticulate dispersion comprises dispersing at least one active agent in a liquid dispersion medium in which the active agent is poorly soluble.
  • a liquid dispersion medium can be, for example, water, aqueous salt solutions, oils such as safflower oil, and solvents such as ethanol, t-butanol, hexane, and glycol.
  • the active agent particles can be reduced in size in the presence of at least one surface stabilizer.
  • the active agent particles may be contacted with one or more surface stabilizers after attrition.
  • Other compounds, such as a diluent, can be added to the active agent/surface stabilizer composition during the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode. The resultant nanoparticulate active agent dispersion can be used directly in formulating a dosage form, or the dispersion can be formulated into a powder followed by dosage formulation.
  • Another method of forming the desired nanoparticulate composition is by microprecipitation.
  • This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities.
  • Such a method comprises, for example: (1) dissolving the poorly water-soluble active agent in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer to form a solution; and (3) precipitating the formulation from step (2) using an appropriate non-solvent.
  • the method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means.
  • the resultant nanoparticulate active agent dispersion can be used directly in formulating a dosage form, or the dispersion can be formulated into a powder followed by dosage formulation.
  • Such a method comprises dispersing active agent particles in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of the active agent particles to the desired effective average particle size.
  • the active agent particles can be reduced in size in the presence of at least one surface stabilizer.
  • the active agent particles can be contacted with one or more surface stabilizers either before or after particle size reduction.
  • disperse the active agent particles in the liquid dispersion medium in the presence of the at least one surface stabilizer as an aid to wetting of the active agent particles.
  • Other compounds, such as a diluent, can be added to the active agent/surface stabilizer composition either before, during, or after the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode. The resultant nanoparticulate active agent dispersion can be used directly in formulating a dosage form, or the dispersion can be formulated into a powder followed by dosage formulation.
  • nanoparticulate active agent particles having at least one surface stabilizer adsorbed on to the surface of the particles can be incorporated into a dry powder matrix (e.g., through spray drying, spray granulation, or a related pharmaceutically acceptable drying process), and combined with bulk micronized active agent particles by dry blending or a similar mixing process.
  • a dry powder matrix e.g., through spray drying, spray granulation, or a related pharmaceutically acceptable drying process
  • nanoparticulate active agent particles can be incorporated into a dry powder matrix (e.g., through spray drying, spray granulation, or a related pharmaceutically acceptable drying process).
  • micronized active agent particles can be incorporated into a dry powder matrix using a similar approach, and the resulting matrices can then be combined by dry blending or a similar mixing process.
  • micronized active agent particles can be prepared by dry milling (e.g., jet milling or pin milling).
  • micronized active agent particles can be prepared by wet milling, similar to the approach employed in the preparation of nanoparticulate active agent particles described in the '684 patent.
  • micronized active agent particles can be employed as the substrate (or a portion thereof) in a spray granulation, rotogranulation, spray coating, or related pharmaceutical process, upon which nanoparticulate active agent particles can be dispersed or deposited to form an outer layer. This particular approach facilitates the release of nanoparticulate active agent particles from the outer layer of the matrix upon exposure to biological fluids, followed by exposure and subsequent dissolution of micronized active agent particles.
  • micronized active agent particles can be employed as the substrate (or a portion thereof) in a high-shear granulation or related pharmaceutical wet-mixing process, upon which nanoparticulate active agent particles can be applied in the form of a granulating fluid.
  • this particular approach enable nanoparticulate active agent particles and micronized active agent particles to be homogeneously distributed in the resulting solid matrix.
  • nanoparticulate active agent particles and micronized active agent particles can exist in the form of a dry powder or powder blend suitable for incorporation into a solid, rapidly disintegrating or "waterless tablet” matrix, the latter being attained upon compression of the dry powder or powder blend using a tablet press or similar pharmaceutically acceptable compression machine.
  • Dosage forms of nanoparticulate dispersions can be prepared by drying the nanoparticulate formulation following size reduction.
  • a preferred drying method is spray drying. The spray drying process is used to obtain a nanoparticulate powder following the size reduction process used to transform the active agent into nanoparticulate sized particles.
  • the nanoparticulate active agent suspension is fed to an atomizer using a peristaltic pump and atomized into a fine spray of droplets.
  • the spray is contacted with hot air in the drying chamber resulting in the evaporation of moisture from the droplets.
  • the resulting spray is passed into a cyclone where the powder is separated and collected.
  • the nanoparticulate dispersion can be spray-dried in the presence or absence of excipients to give the spray-dried intermediate powder.
  • the powder can be formulated, for example, into a tablet, suppository, or other solid dosage form, or the powder can be formulated into an aerosol for nasal or pulmonary administration.
  • the powder can also be reconstituted into a liquid, and used, for example, for injectable, ocular, ear, or oral dosage forms.
  • Solid dose forms of nanoparticulate dispersions can also be prepared by lyophilizing the nanoparticulate formulation following size reduction.
  • Suitable lyophilization conditions include, for example, those described in EP 0,363,365 (McNeil-PPC Inc.), U.S. Patent No. 4,178,695 (A. Erbeia), and U.S. Patent No.
  • the nanoparticulate dispersion is placed in a suitable vessel and frozen to a temperature of between about -5°C to about -100°C.
  • the frozen dispersion is then subjected to reduced pressure for a period of up to about 48 hours.
  • the combination of parameters such as temperature, pressure, dispersion medium, and batch size will impact the time required for the lyophilization process.
  • the frozen solvent is removed by sublimation yielding a solid, porous, IR solid dosage form having the active ingredient distributed throughout.
  • the powder can be formulated, for example, into a tablet, suppository, or other solid dosage form, or the powder can be formulated into an aerosol for nasal or pulmonary administration.
  • the powder can also be reconstituted into a liquid, and used, for example, for injectable, ocular, ear, or oral dosage forms. c. Granulation
  • a solid oral dosage form of the invention can be prepared by granulating in a fluidized bed an admixture comprising a nanoparticulate dispersion of active agent and at least one surface stabilizer with a solution of at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, to form a granulate. This is followed by tableting of the granulate to form a solid dosage form.
  • the dosage formulations of the invention can be in the form of tablets. Preparation of such tablets can be by pharmaceutical compression or molding techniques known in the art.
  • the tablets of the invention may take any appropriate shape, such as discoid, round, oval, oblong, cylindrical, triangular, hexagonal, and the like.
  • Powders for tableting can be formulated into tablets by any method known in the art. Suitable methods include, but are not limited to, milling, fluid bed granulation, dry granulation, direct compression, spheronization, spray congealing, and spray-dying.
  • the tablets may be coated or uncoated. If coated they may be sugar-coated (to cover objectionable tastes or odors and to protect against oxidation) or film coated (a thin film of water soluble matter for similar purposes).
  • the present invention provides a method of treating a mammal, including a human, requiring the rapid availability of at least one poorly soluble active ingredient in combination with controlled release of the same or a different poorly soluble active ingredient.
  • the administered compositions of the invention rapidly release an incorporated active agent resulting in fast onset of activity, and simultaneously slowly release the same or a different active agent for a prolonged pharmacological effect.
  • compositions of the invention will be administered to a mammalian subject in need thereof using a level of drug or active agent that is sufficient to provide the desired physiological effect.
  • the mammalian subject may be a domestic animal or pet but preferably is a human subject.
  • the level of drug or active agent needed to give the desired physiological result is readily determined by one of ordinary skill in the art by referring to standard texts, such as Goodman and G ⁇ llman and the Physician 's Desk Reference .
  • Example 1 The purpose of this example was to simulate, using a mathematical model, pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing an active agent having a single defined particle size.
  • the software used for the simulation was MicroMath PKAnalyst for Windows, version 1.1, MicroMath, Inc.
  • K 21 0.125 h "1 (constant representing the rate of diffusion from the peripheral compartment to the central compartment).
  • the small particle population (S) showed rapid onset of activity, peaking at a plasma concentration level of about 2100 mg/mL at a little over 1 hour following administration, with plasma levels of over 250 mg/mL several minutes following administration. However, this sample also exhibited the lowest plasma levels at 12 hours after administration.
  • the large particle population (L) showed slow onset of activity, peaking at a plasma concentration level of a little over 500 mg/mL at about 2 hours after administration.
  • this sample also exhibited the highest plasma levels at 12 hours after administration.
  • the purpose of this example was to simulate, using a mathematical model, pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing mixtures of different sizes of particles.
  • Example 2 Simulated pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing 50:50 mixtures of small (S) particles plus medium-small (MS), medium-large (ML), or large (L) particles of an active pharmaceutical ingredient are shown in Figure 2.
  • Example 3 The purpose of this example was to simulate, using a mathematical model, pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing mixtures of different sizes of particles. The assumptions described in Example 1 are applicable to Example 3.

Abstract

Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.

Description

COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
FIELD OF THE INVENTION
The present invention relates to compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one poorly soluble active ingredient having a microparticulate particle size.
BACKGROUND OF THE INVENTION
A. Background Regarding Nanoparticulate Compositions
Nanoparticulate compositions, first described in U.S. Patent No. 5,145,684 ("the '684 patent"), are particles consisting of a poorly soluble active agent having adsorbed onto the surface thereof a non-crosslinked surface stabilizer. The '684 patent also describes methods of making such nanoparticulate compositions. Nanoparticulate compositions are desirable because with a decrease in particle size, and a consequent increase in surface area, a composition is rapidly dissolved and absorbed following administration. Methods of making such compositions are described in U.S. Patent Nos. 5,518,187 and 5,862,999, both for "Method of Grinding Pharmaceutical Substances," U.S. Patent No. 5,718,388, for "Continuous Method of Grinding Pharmaceutical Substances;" and U.S. Patent No. 5,510,118 for "Process of Preparing Therapeutic Compositions Containing Nanoparticles."
Nanoparticulate compositions are also described in, for example, U.S. Patent Nos. 5,298,262 for "Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" 5,302,401 for "Method to Reduce Particle Size Growth During Lyophilization;" 5,318,767 for "X-Ray Contrast Compositions Useful in Medical Imaging;" 5,326,552 for "Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;" 5,328,404 for "Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;" 5,336,507 for "Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;" 5,340,564 for "Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;" 5,346,702 for "Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticulate Aggregation During Sterilization;" 5,349,957 for "Preparation and Magnetic Properties of Very Small Magnetic-Dextran Particles;" 5,352,459 for "Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization;" 5,399,363 and 5,494,683, both for "Surface Modified Anticancer Nanoparticles;" 5,401,492 for "Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents;" 5,429,824 for "Use of Tyloxapol as a Nanoparticulate Stabilizer;" 5,447,710 for "Method for Making Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;" 5,451,393 for "X-Ray Contrast Compositions Useful in Medical Imaging;" 5,466,440 for "Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents in Combination with Pharmaceutically Acceptable Clays;" 5,470,583 for "Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation;" 5,472,683 for "Nanoparticulate Diagnostic Mixed Carbamic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,500,204 for "Nanoparticulate Diagnostic Dimers as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,518,187 for "Method of Grinding Pharmaceutical Substances;" 5,518,738 for "Nanoparticulate NSAID Formulations;" 5,521,218 for "Nanoparticulate Iododipamide Derivatives for Use as X-Ray Contrast Agents;" 5,525,328 for "Nanoparticulate Diagnostic Diatrizoxy Ester X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,543,133 for "Process of Preparing X- Ray Contrast Compositions Containing Nanoparticles;" 5,552,160 for "Surface Modified NSAID Nanoparticles;" 5,560,931 for "Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;" 5,565,188 for "Polyalkylene Block Copolymers as Surface Modifiers for Nanoparticles;" 5,569,448 for "Sulfated Non-ionic Block Copolymer Surfactant as Stabilizer Coatings for Nanoparticle Compositions;" 5,571,536 for "Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;" 5,573,749 for
"Nanoparticulate Diagnostic Mixed Carboxylic Anydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,573,750 for "Diagnostic Imaging X- Ray Contrast Agents;" 5,573,783 for "Redispersible Nanoparticulate Film Matrices With Protective Overcoats;" 5,580,579 for "Site-specific Adhesion Within the GI Tract Using Nanoparticles Stabilized by High Molecular Weight, Linear Poly(ethylene Oxide) Polymers;" 5,585,108 for "Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays;" 5,587,143 for "Butylene Oxide-Ethylene Oxide Block Copolymers Surfactants as Stabilizer Coatings for Nanoparticulate Compositions;" 5,591,456 for "Milled Naproxen with Hydropropyl Cellulose as Dispersion Stabilizer;" 5,593,657 for "Novel Barium Salt Formulations Stabilized by Non-ionic and Anionic Stabilizers;" 5,622,938 for "Sugar Based Surfactant for Nanocrystals;" 5,628,981 for "Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal
Therapeutic Agents;" 5,643,552 for "Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances;" 5,718,919 for "Nanoparticles Containing the R(-)Enantiomer of Ibuprofen;" 5,747,001 for "Aerosols Containing Beclomethasone Nanoparticle Dispersions;" 5,834,025 for "Reduction of Intravenously Administered Nanoparticulate Formulation Induced Adverse Physiological Reactions;" 6,045,829 "Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers;" 6,068,858 for "Methods of Making Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers;" 6,153,225 for "Injectable Formulations of Nanoparticulate Naproxen;" 6,165,506 for "New Solid Dose Form of Nanoparticulate Naproxen;" 6,221,400 for "Methods of Treating Mammals Using Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors;" 6,264,922 for "Nebulized Aerosols Containing Nanoparticle Dispersions;" 6,267,989 for "Methods for Preventing Crystal Growth and Particle Aggregation in Nanoparticle Compositions;" 6,270,806 for "Use of PEG-Derivatized Lipids as Surface Stabilizers for Nanoparticulate Compositions;" 6,316,029 for "Rapidly Disintegrating Solid Oral Dosage Form," 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate;" 6,428,814 for "Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers;" and 6,432,381 for "Methods for Targeting Drug Delivery to the Upper and/or Lower Gastrointestinal Tract," all of which are specifically incorporated by reference. In addition, U.S. Patent Application No. 20020012675 Al, published on January 31, 2002, for "Controlled Release Nanoparticulate Compositions," describes nanoparticulate compositions, and is specifically incorporated by reference.
Amorphous small particle compositions are described in, for example, U.S. Patent Nos. 4,783,484 for "Particulate Composition and Use Thereof as Antimicrobial Agent," 4,826,689 for "Method for Making Uniformly Sized Particles from Water- Insoluble Organic Compounds," 4,997,454 for "Method for Making Uniformly-Sized Particles From Insoluble Compounds," 5,741,522 for "Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods," and 5,776,496, for "Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter.
None of these references, or any other reference that describes nanoparticulate compositions, relates to a nanoparticulate composition having a combination of immediate release and controlled release characteristics.
B. Background Regarding Immediate Release Compositions Conventional immediate release dosage forms, also referred to as "fast melt" or
"rapidly disintegrating" dosage forms, rely on the composition of the drug matrix to effect the rapid release of the component active agent particles, rather than the particle size of the component active agent particles.
Current manufacturers of rapidly disintegrating or dissolving solid dose oral formulations include Cima Labs, Fuisz Technologies Ltd., Prographarm, R.P. Scherer, and Yamanouchi-Shaklee. All of these manufacturers market different types of rapidly dissolving solid oral dosage forms.
Cima Labs markets OraSolv®, which is an effervescent direct compression tablet having an oral dissolution time of five to thirty seconds, and DuraSolv®, which is a direct compression tablet having a taste-masked active agent and an oral dissolution time of 15 to 45 seconds. Cima's U.S. Patent No. 5,607,697, for "Taste Masking Microparticles for Oral Dosage Forms," describes a solid dosage form consisting of coated microparticles that disintegrate in the mouth. The microparticle core has a pharmaceutical agent and one or more sweet-tasting compounds having a negative heat of solution selected from mannitol, sorbitol, a mixture of an artificial sweetener and menthol, a mixture of sugar and menthol, and methyl salicylate. The microparticle core is coated, at least partially, with a material that retards dissolution in the mouth and masks the taste of the pharmaceutical agent. The microparticles are then compressed to form a tablet. Other excipients can also be added to the tablet formulation.
WO 98/46215 for "Rapidly Dissolving Robust Dosage Form," assigned to Cima Labs, is directed to a hard, compressed, fast melt formulation having an active ingredient and a matrix of at least a non-direct compression filler and lubricant. A non- direct compression filler is typically not free-flowing, in contrast to a direct compression (DC grade) filler, and usually requires additionally processing to form free-flowing granules.
Cima also has U.S. patents and international patent applications directed to effervescent dosage forms (U.S. Patent Nos. 5,503,846, 5,223,264, and 5,178,878) and tableting aids for rapidly dissolving dosage forms (U.S. Patent Nos. 5,401,513 and 5,219,574), and rapidly dissolving dosage forms for water soluble drugs (WO 98/14179 for "Taste-Masked Microcapsule Composition and Methods of Manufacture").
Fuisz Technologies, now part of BioVail, markets Flash Dose®, which is a direct compression tablet containing a processed excipient called Shearform®. Shearform® is a cotton candy-like substance of mixed polysaccharides converted to amorphous fibers. U.S. patents describing this technology include U.S. Patent No. 5,871,781 for "Apparatus for Making Rapidly Dissolving Dosage Units;" U.S. Patent No. 5,869,098 for "Fast-Dissolving Comestible Units Formed Under High-Speed/High-Pressure Conditions;" U.S. Patent Nos. 5,866,163, 5,851,553, and 5,622,719, all for "Process and Apparatus for Making Rapidly Dissolving Dosage Units and Product Therefrom;" U.S. Patent No. 5,567,439 for "Delivery of Controlled-Release Systems;" and U.S. Patent No. 5,587,172 for "Process for Forming Quickly Dispersing Comestible Unit and Product Therefrom." Prographarm markets Flashtab®, which is a fast melt tablet having a disintegrating agent such as carboxymethyl cellulose, a swelling agent such as a modified starch, and a taste-masked active agent. The tablets have an oral disintegration time of under one minute (U.S. Patent No. 5,464,632).
R.P. Scherer markets Zydis®, which is a freeze-dried tablet having an oral dissolution time of 2 to 5 seconds. Lyophilized tablets are costly to manufacture and difficult to package because of the tablets sensitivity to moisture and temperature. U.S. Patent No. 4,642,903 (R.P. Scherer Corp.) refers to a fast melt dosage formulation prepared by dispersing a gas throughout a solution or suspension to be freeze-dried. U.S. Patent No. 5,188,825 (R.P. Scherer Corp.) refers to freeze-dried dosage forms prepared by bonding or complexing a water-soluble active agent to or with an ion exchange resin to form a substantially water insoluble complex, which is then mixed with an appropriate carrier and freeze dried. U.S. Patent No. 5,631,023 (R. P. Scherer Corp.) refers to freeze-dried drug dosage forms made by adding xanthan gum to a suspension of gelatin and active agent. U.S. Patent No. 5,827,541 (R.P. Scherer Corp.) discloses a process for preparing solid pharmaceutical dosage forms of hydrophobic substances. The process involves freeze-drying a dispersion containing a hydrophobic active ingredient and a surfactant in a non-aqueous phase and a carrier material in an aqueous phase.
Yamanouchi-Shaklee markets Wowtab®, which is a tablet having a combination of a low moldability and a high moldability saccharide. U.S. Patents covering this technology include U.S. Patent No. 5,576,014 for "Intrabuccally Dissolving Compressed Moldings and Production Process Thereof," and U.S. Patent No. 5,446,464 for "Intrabuccally Disintegrating Preparation and Production Thereof."
Other companies owning rapidly dissolving technology include Janssen Pharmaceutica. U.S. patents assigned to Janssen describe rapidly dissolving tablets having two polypeptide (or gelatin) components and a bulking agent, wherein the two components have a net charge of the same sign, and the first component is more soluble in aqueous solution than the second component. See U.S. Patent No. 5,807,576 for "Rapidly Dissolving Tablet;" U.S. Patent No. 5,635,210 for "Method of Making a Rapidly Dissolving Tablet;" U.S. Patent No. 5,595,761 for "Particulate Support Matrix for Making a Rapidly Dissolving Tablet;" U.S. Patent No. 5,587,180 for "Process for Making a Particulate Support Matrix for Making a Rapidly Dissolving Tablet;" and U.S. Patent No. 5,776,491 for "Rapidly Dissolving Dosage Form."
Eurand America, Inc. has U.S. patents directed to a rapidly dissolving effervescent composition having a mixture of sodium bicarbonate, citric acid, and ethylcellulose (U.S. Patent Nos. 5,639,475 and 5,709,886).
L.A.B. Pharmaceutical Research owns U.S. patents directed to effervescent- based rapidly dissolving formulations having an effervescent couple of an effervescent acid and an effervescent base (U.S. Patent Nos. 5,807,578 and 5,807,577).
Schering Corporation has technology relating to buccal tablets having an active agent, an excipient (which can be a surfactant) or at least one of sucrose, lactose, or sorbitol, and either magnesium stearate or sodium dodecyl sulfate (U.S. Patent Nos. 5,112,616 and 5,073,374).
Laboratoire L. LaFon owns technology directed to conventional dosage forms made by lyophilization of an oil-in-water emulsion in which at least one of the two phases contains a surfactant (U.S. Patent No. 4,616,047). For this type of formulation, the active ingredient is maintained in a frozen suspension state and is tableted without micronization or compression, as such processes could damage the active agent.
Takeda Chemicals Inc., Ltd. owns technology directed to a method of making a fast dissolving tablet in which an active agent and a moistened, soluble carbohydrate are compression molded into a tablet, followed by drying of the tablets.
None of the described prior art teaches an immediate release dosage form in which a poorly soluble active ingredient is in a nanoparticulate form. This is significant because the prior art immediate release formulations do not address the problems associated with the bioavailability of poorly soluble drugs. While prior art immediate release dosage forms may provide rapid presentation of a drug, frequently there is an undesirable lag in the onset of therapeutic action because of the poor solubility and associated slow dissolution rate of the drug. Thus, while prior art immediate release dosage forms may exhibit rapid disintegration of the drug carrier matrix, this does not result in rapid dissolution and absorption of the poorly soluble drug contained within the dosage form.
C. Background Regarding Controlled Release Compositions
Controlled release refers to the release of an agent such as a drug from a composition or dosage form in which the agent is released according to a desired profile over an extended period of time. Controlled release profiles include, for example, sustained release, prolonged release, pulsatile release, and delayed release profiles. In contrast to immediate release compositions, controlled release compositions allow delivery of an agent to a subject over an extended period of time according to a predetermined profile. Such release rates can provide therapeutically effective levels of agent for an extended period of time and thereby provide a longer period of pharmacologic or diagnostic response as compared to conventional rapid release dosage forms. Such longer periods of response provide for many inherent benefits that are not achieved with the corresponding short acting, immediate release preparations. For example, in the treatment of chronic pain, controlled release formulations are often highly preferred over conventional short-acting formulations.
Controlled release pharmaceutical compositions and dosage forms are designed to improve the delivery profile of agents, such as drugs, medicaments, active agents, diagnostic agents, or any substance to be internally administered to an animal, including humans. A controlled release composition is typically used to improve the effects of administered substances by optimizing the kinetics of delivery, thereby increasing bioavailability, convenience, and patient compliance, as well as minimizing side effects associated with inappropriate immediate release rates such as a high initial release rate and, if undesired, uneven blood or tissue levels.
Prior art teachings of the preparation and use of compositions providing for controlled release of an active compound provide various methods of extending the release of a drug following administration.
Exemplary controlled release formulations known in the art include specially coated pellets, microparticles, implants, tablets, minitabs, and capsules in which a controlled release of a drug is brought about, for example, through selective breakdown of the coating of the preparation, through release through the coating, through compounding with a special matrix to affect the release of a drug, or through a combination of these techniques. Some controlled release formulations provide for pulsatile release of a single dose of an active compound at predetermined periods after administration.
U.S. Patent No. 5,110,605 to Acharya et al. refers to a calcium polycarbophil- alginate controlled release composition. U.S. Patent No. 5,215,758 to Krishnamurthy et al. refers to a controlled release suppository composition of sodium alginate and calcium salt. U.S. Patent No. 5,811,388 to Friend et al. refers to a solid alginate-based formulation including alginate, a water-swellable polymer, and a digestible hydrocarbon derivative for providing controlled release of orally administered compounds. WO 91/13612 refers to the sustained release of pharmaceuticals using compositions in which the drug is complexed with an ion-exchange resin. The specific ion-exchange resin described in this published patent application is AMBERLiTE IRP 69®, a sodium polystyrene sulphonate resin. U.S. Patent No. 5,811,425 to Woods et al. refers to injectable depot forms of controlled release drugs made by forming microencapsule matrices of the drug in biodegradable polymers, liposomes, or microemulsions compatible with body tissues. U.S. Patent No. 5,811,422 to Lam et al. refers to controlled release compositions obtained by coupling a class of drugs to biodegradable polymers, such as polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, etc.
U.S. Patent No. 5,811,404 to De Frees et al. refers to the use of liposomes having prolonged circulation half-lives to provide for the sustained release of drug compositions.
Finally, WO 00/18374, for "Controlled Release Nanoparticulate Compositions," describes controlled release formulations comprising nanoparticulate active agents.
There is a need in the art for compositions of poorly soluble drugs having a combination of immediate release and controlled release characteristics. The present invention satisfies this need.
SUMMARY OF THE INVENTION This invention is directed to the surprising and unexpected discovery of formulations of poorly soluble active agents having a combination of immediate active agent release and controlled active agent release characteristics. The formulations comprise a combination of very small active agent particles, i.e., nanoparticulate active agent particles, in combination with larger active agent particles, i.e., micronized active agent particles, which enable obtaining the simultaneous presentation of immediate- release (TR) and controlled-release (CR) active agent components.
The nanoparticulate active agent particles, representing the IR component, afford rapid in vivo dissolution, owing to their small size and attendant large specific surface. Alternatively, micronized active agent particles, representing the CR component, afford slower in vivo dissolution, owing to a comparatively large particle size and small attendant specific surface.
IR and CR components representing a wide range of in vivo dissolution rates (and hence, in vivo input rates for absorption) can be engineered through precise control of active agent particle size. Thus, the compositions can comprise a mixture of nanoparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate, and the compositions can comprise a mixture of microparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate.
The compositions of the invention are highly unexpected, particularly since the controlled delivery of active agents has traditionally been achieved through employment of rate-controlling membranes, swellable and erodible polymers, and ion-exchange resins, rather than solely through the particle size of the active agent component of the dosage form.
In another aspect of the invention there is provided a method of preparing formulations having a combination of IR and CR characteristics. The method comprises: (1) forming a composition comprising particles of at least one nanoparticulate active agent to be administered and at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles; (2), adding at least one microparticulate active agent, which can be the same or different from the active agent of (1), and (3) forming a dosage form of the mixture of (1) and (2) for administration. Additional pharmaceutically acceptable excipients can also be added to the composition for administration. Yet another aspect of the present invention provides a method of treating a mammal, including a human, with a composition of the invention.
It is to be understood that both the foregoing general description and the following brief description of the figures and detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1: Shows a simulation, using a mathematical model, of pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing an active agent having a single defined particle size; FIGURE 2: Shows a simulation, using a mathematical model, of pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing mixtures of different sizes of particles; and
FIGURE 3: Shows a simulation, using a mathematical model, of pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing mixtures of different sizes of particles.
DETAILED DESCRIPTION OF THE INVENTION A. Compositions
This invention is directed to the surprising and unexpected discovery of new compositions exhibiting a combination of IR and CR characteristics. The compositions do not require the presence of an additional ingredient, such as a rate controlling polymer or membrane, a swellable or erodible polymer, or ion-exchange resin, to obtain the CR characteristics. The IR and CR characteristics are obtained using precisely calibrated particle sizes for the one or more active agents. Smaller particle sizes result in IR profiles and larger particle sizes result in CR profiles.
The compositions of the invention comprise: (1) particles of at least one poorly soluble nanoparticulate active agent; (2) at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles; and (3) at least one poorly soluble microparticulate active agent, which can be the same as or different from the active agent of (1). As taught in the '684 patent, the surface stabilizer functions to stabilize the nanoparticulate active agent by preventing agglomeration and particle size growth.
Methods of making nanoparticulate active agent compositions, which can comprise mechanical grinding, precipitation, homogenization, or any other suitable size reduction process, are known in the art and are described in, for example, the '684 patent and other prior art references disclosed in the "Background of the Invention."
The nanoparticulate and microparticulate active agent particles can be in a crystalline form, semi-crystalline form, amorphous form, semi-amorphous form, or a combination thereof.
The compositions can be formulated for administration to humans and animals via any conventional means, including but not limited to orally, rectally, parenterally (intravenous, intramuscular, or subcutaneous), intracisternally, pulmonary, intravaginally, intraperitoneally, locally (powders, ointments or drops), ocularly, aurally, or as a buccal or nasal spray.
The present invention also encompasses the compositions of the invention formulated together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers. The compositions can be formulated for parenteral injection, oral administration in solid or liquid form, rectal or topical administration, ocular or aural administration, and the like.
For oral dosage forms, the IR component results in rapid dissolution of the poorly soluble active agent in the oral cavity as a result of the nanoparticulate size of the drug. Further, the opportunity for buccal absorption of the poorly soluble active ingredient is enhanced with the present invention. Yet another advantage of the nanoparticulate IR component is that the use of nanoparticulate active agent particles eliminates or minimizes the feeling of grittiness found with prior art IR oral formulations of poorly soluble active agents.
One advantage typically associated with IR dosage forms is a reduction of the time lag between administration of a dose and the physical presentation of the active ingredient. This lag time is usually associated with the break up of the dosage form and the distribution of the active ingredient thereafter. Another advantage of oral JJR. dosage forms is that the rapid presentation of the active agent in the mouth upon administration may facilitate buccal absorption of the active ingredient directly into the blood stream, thus reducing the first pass effect of the liver on the overall bioavailability of active ingredient from a unit dose. This second advantage is dramatically enhanced for the IR formulations of the invention, as the nanoparticulate size of the active agent enables rapid dissolution in the oral cavity.
It is expected that the CR component of the compositions provides effective blood levels of an incorporated active agent in a patient for an extended period of time. As used herein, "controlled release" means the release of an active agent such as a drug from a composition or dosage form in which the agent is released according to a desired profile over an extended period of time, such as from about 2 to about 24 hours or longer. Release over a longer time period is also contemplated as a "controlled release" dosage form of the present invention. An exemplary formulation is graphically illustrated below:
Figure imgf000015_0001
1. Solid Dosage Forms In a first embodiment of the invention, both of the IR and CR components are incorporated in a solid, rapidly disintegrating or "waterless tablet" matrix intended for oral administration.
In a second embodiment of the invention, the IR and CR components are combined in a pharmaceutically acceptable tablet intended for oral administration. In a third embodiment of the invention, the IR and CR components are combined in a pharmaceutically acceptable hard gelatin capsule intended for oral administration.
In a fourth embodiment of the invention, the IR and CR components are combined in a pharmaceutically acceptable soft gelatin capsule intended for oral administration. One variation of this dosage form comprises solubilized drag and microparticulate drug particles, in which the solubilized drug functions as the IR component and the microparticulate drug particles function as the CR component of the dosage form. This variation differs from the other dosage forms described herein in that it does not require the presence of "particulate" nanoparticulate drug particles. In a fifth embodiment of the invention, the IR and CR components are combined in a pharmaceutically acceptable lozenge or troche intended for oral administration. In a sixth embodiment of the invention, the IR and CR components are combined in a pharmaceutically acceptable sachet, powder, or "sprinkle" intended for oral administration.
2. Other Dosage Forms
Other suitable dosage forms include, but are not limited to, suppositories for rectal or intravaginally use; injectables, including injectables for intravenous, intramuscular, or subcutaneous administration; aerosols for pulmonary or nasal administration; buccal dosage forms; dosage forms for local application, such as powders, ointments, or drops; ocular and aural dosage forms, and dosage forms for intracisternal and intraperitoneal administration.
The IR and CR compositions of the invention can be combined in any pharmaceutically acceptable dosage form, which is not limited to those specifically described above.
3. Poorly Soluble Active Agent
The compositions of the invention comprise at least one poorly soluble therapeutic agent, diagnostic agent, or other active agent. A therapeutic agent can be a drug or pharmaceutical and a diagnostic agent is typically a contrast agent, such as an x- ray contrast agent, or any other type of diagnostic material.
The invention can be practised with a wide variety of poorly soluble drugs or diagnostic agents. The drug or diagnostic agent is preferably present in an essentially pure form, is poorly soluble, and is dispersible in at least one liquid medium. By "poorly soluble" it is meant that the drug or diagnostic agent has a solubility in a liquid dispersion medium of less than about 30 mg/ml, preferably less than about 10 mg/ml, and more preferably less than about 1 mg/ml. Such a liquid dispersion medium can be, for example, water, aqueous salt solutions, oils such as safflower oil, and solvents such as ethanol, t-butanol, hexane, and glycol.
The poorly soluble active agent can be selected from a variety of known classes of drugs or diagnostic agents, including, for example, proteins, peptides, nucleotides, anti-obesity drugs, nutraceuticals, corticosteroids, elastase inhibitors, analgesics, anti- fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti- inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives (e.g., hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio- pharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators and xanthines. Exemplary nutraceuticals and dietary supplements are disclosed, for example, in Roberts et al., Nutraceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and Healing Foods (American Nutraceutical Association, 2001), which is specifically incorporated by reference. A nutraceutical or dietary supplement, also known as phytochemicals or functional foods, is generally any one of a class of dietary supplements, vitamins, minerals, herbs, or healing foods that have medical or pharmaceutical effects on the body. Exemplary nutraceuticals or dietary supplements include, but are not limited to, folic acid, fatty acids (e.g., DHA and ARA), fruit and vegetable extracts, vitamin and mineral supplements, phosphatidylserine, lipoic acid, melatonin, glucosamine/chondroitin, Aloe Vera, Guggul, glutamine, amino acids (e.g., iso-leucine, leucine, lysine, methionine, phenylanine, threonine, tryptophan, and valine), green tea, lycopene, whole foods, food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flax seeds, fish and marine animal oils, and probiotics. Nutraceuticals and dietary supplements also include bio- engineered foods genetically engineered to have a desired property, also known as "pharmafoods."
The active agents are commercially available and/or can be prepared by techniques known in the art. The poorly soluble active ingredient may be present in any amount which is sufficient to elicit a therapeutic effect and, where applicable, may be present either substantially in the form of one optically pure enantiomer or as a mixture, racemic or otherwise, of enantiomers. 4. Surface Stabilizers
Useful surface stabilizers, which are known in the art and described, for example, in the '684 patent, are believed to include those which physically adhere to the surface of the active agent but do not chemically bond to or interact with the active agent. The surface stabilizer is adsorbed on the surface of the nanoparticulate active agent in an amount sufficient to maintain an effective average particle size of less than about 1000 nm for the active agent. Furthermore, the individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages. Two or more surface stabilizers can be employed in the compositions and methods of the invention.
Suitable surface stabilizers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Preferred surface stabilizers include nonionic and ionic surfactants, including anionic and cationic surfactants.
Representative examples of surface stabilizers include gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80® (ICI Speciality Chemicals)); polyethylene glycols (e.g., Carbowaxs 3550® and 934® (Union Carbide)), polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), 4-(l,l,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronics F68® and F108®, which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Wyandotte Corporation, Parsippany, NJ.)); Tetronic 1508® (T-1508) (BASF Wyandotte Corporation ), dialkylesters of sodium sulfosuccinic acid (e.g., Aerosol OT®, which is a dioctyl ester of sodium sulfosuccinic acid (American Cyanamid)); Duponol P®, which is a sodium lauryl sulfate (DuPont); Tritons X-200®, which is an alkyl aryl polyether sulfonate (Rohm and Haas); Crodestas F-110®, which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isononylphenoxypoly-(glycidol), also known as Olin-IOG® or Surfactant 10-G®(Olin Chemicals, Stamford, CT); Crodestas SL-40® (Croda, Inc.); and SA9OHCO, which is Ci8H37CH2C(O)N(CH3)-CH2(CHOH)4(CH2θH)2 (Eastman Kodak Co.); decanoyl-N-methylglucamide; n-decyl β-D-glucopyranoside; n-decyl β-D- maltopyranoside; n-dodecyl β-D-glucopyranoside; n-dodecyl β-D-maltoside; heptanoyl- N-methylglucamide; n-heptyl-β-D-glucopyranoside; n-heptyl β-D-thioglucoside; n- hexyl β-D-glucopyranoside; nonanoyl-N-methylglucamide; n-noyl β-D- glucopyranoside; octanoyl-N-methylglucamide; n-octyl-β-D-glucopyranoside; octyl β- D-thioglucopyranoside; lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate, such as Plasdone S630, PEG-derivatized phospholipids, PEG-derivatized cholesterol, PEG-derivatized cholesterol derivatives, PEG-derivatized vitamin A, PEG- derivatized vitamin E, and the like.
Other useful surface stabilizers include sodium lauryl sulfate, dioctyl sodium sulfosuccinate, or a combination thereof. Examples of useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-mefhylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
Other useful cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C12.15dimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy)4 ammonium chloride or bromide, N- alkyl (Cι2_18)dimethylbenzyl ammonium chloride, N-alkyl (C14.18)dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (Cι2_ι ) dimethyl 1-naρthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts and dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt and/or an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N- tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C12_ι4) dimethyl 1-naphthylmethyl ammonium chloride and dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C12, Cι5, C1 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride (ALIQUAT 336™), POLYQUAT 10™, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters (such as choline esters of fatty acids), benzalkonium chloride, stearalkonium chloride compounds (such as stearyltrimonium chloride and Di- stearyldimonium chloride), cetyl pyridinium bromide or chloride, halide salts of quaternized polyoxyethylalkylamines, MIRAPOL™ and ALKAQUAT™ (Alkaril Chemical Company), alkyl pyridinium salts; amines, such as alkylamines, dialkylamines, alkanolamines, polyethylenepolyamines, N,N-dialkylaminoalkyl acrylates, and vinyl pyridine, amine salts, such as lauryl amine acetate, stearyl amine acetate, alkylpyridinium salt, and alkylimidazolium salt, and amine oxides; imide azolinium salts; protonated quaternary acrylamides; methylated quaternary polymers, such as ρoly[diallyl dimethylammonium chloride] and poly-[N-methyl vinyl pyridinium chloride]; and cationic guar.
Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990).
Particularly preferred nonpolymeric primary stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR1R2R3R4 (+). For compounds of the formula NR1R2R3R4 (+): (i) none of Ri-R4 are CH3; (ii) one of R R is CH3; (iii) three of R\ -R4 are CH3 ; (iv) all of Rι-R4 are CH3; (v) two of Rι-R are CH , one of Rι-R4 is C6H5CH2, and one of R R4 is an alkyl chain of seven carbon atoms or less; (vi) two of R R are CH3, one of Rι-R4 is C6H5CH2, and one of R R4 is an alkyl chain of nineteen carbon atoms or more; (vii) two of Ri-R are CH3 and one of Rι-R is the group C6H5(CH2)n, where n>l ; (viii) two of Ri-R are CH3, one of Rι-R4 is C6H5CH2, and one of R R comprises at least one heteroatom; (ix) two of Rι-R4 are CH3, one of Rι-R is C6H5CH2, and one of Rι-R4 comprises at least one halogen; (x) two of Ri^ are CH3, one of Rι-R4 is C6H5CH , and one of Ri-R comprises at least one cyclic fragment;
(xi) two of Ri^ are CH3 and one of Rι-R4 is a phenyl ring; or
(xii) two of Rι-R4 are CH3 and two of R^R4 are purely aliphatic fragments.
Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammonium chloride(Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbentonite, stearalkonium chloride, domiphen bromide, denatonium benzoate, myristalkonium chloride, laurtrimonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine HCl, iofetamine hydrochloride, meglumine hydrochloride, methylbenzethonium chloride, myrtrimonium bromide, oleyltrimonium chloride, polyquaternium-1, procainehydrochloride, cocobetaine, stearalkonium bentonite, stearalkoniumhectonite, stearyl trihydroxyethyl propylenediamine dihydrofluoride, tallowtrimonium chloride, and hexadecyltrimethyl ammonium bromide.
Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 2000), specifically incorporated by reference. The surface stabilizers are commercially available and/or can be prepared by techniques known in the art.
5. Particle Size
The IR characteristics of the dosage form are obtained by utilizing at least one nanoparticulate active agent having an effective average particle size of less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, or less than about 50 nm.
The CR characteristics of the dosage form are obtained by utilizing at least one microparticulate active agent having an effective average particle size of greater than about 1 micron and less than about 100 microns, less than about 90 microns, less than about 80 microns, less than about 70 microns, less than about 60 microns, less than about 50 microns, less than about 40 microns, less than about 30 microns, less than about 20 microns, less than about 10 microns, less than about 9 microns, less than about 8 microns, less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, less than about 3 microns, or less than about 2 microns.
The compositions can comprise multiple populations of nanoparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate, i.e. a first population having an effective average particle size of less than about 1 micron, a second population having an effective average particle size of less than about 800 nm, a third population having an effective average particle size of less than about 500 nm, a fourth population having an effective average particle size of less than about 50 nm, etc., with each population corresponding to a specific release rate.
Similarly, the compositions can comprise multiple populations of microparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate, i.e. a first population having an effective average particle size of less than about 100 microns, a second population having an effective average particle size of less than about 60 microns, a third population having an effective average particle size of less than about 40 microns, a fourth population having an effective average particle size of less than about 20 microns, etc., with each population corresponding to a specific release rate. Each population of particles in the composition, both nanoparticulate and microparticulate, exhibits a baseline resolution of at least 50%, 60%, 70%, 80%, or 90%. This means that the heterogeneous population is characterized by a multi-modal particle size distribution, with a minimum baseline resolution of 50% relative to two adjacent peaks. 50% baseline resolution is defined as half the distance from the baseline of the distribution to the average height of two adjacent peaks.
The baseline resolution of at least 50% distinguishes the claimed invention from a conventional microparticulate composition having a mixture of particle sizes, as in such a conventional composition the particle sizes are randomly distributed and do not have a baseline resolution of at least 50% for two or more particle sizes. As used herein, particle size is determined on the basis of the weight average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and disk centrifugation.
By "an effective average particle size of less than about 1000 nm" it is meant that at least 50% of the active agent particles have an average particle size of less than about 1000 nm, when measured by the above techniques. Similarly, by "an effective average particle size of less than about 100 microns, it is meant that at least 50% of the active agent particles have an average particle size of less than about 100 microns, when measured by the above techniques. Preferably, at least 70% of the particles have an average particle size of less than the effective average, more preferably at least about 90% of the particles have an average particle size of less than the effective average.
6. Other Pharmaceutical Excipients
Pharmaceutical compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients. Such excipients are known in the art.
Examples of filling agents are lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel® PHI 01 and Avicel® PH102, microcrystalline cellulose, and silicifized microcrystalline cellulose (SMCC). Suitable lubricants, including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil® 200; talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
Examples of sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame. Examples of flavoring agents are Magnasweet® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
Examples of preservatives are potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing. Examples of diluents include microcrystalline cellulose, such as Avicel® PH101 and Avicel® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose® DCL21; dibasic calcium phosphate such as Emcompress®; mannitol; starch; sorbitol; sucrose; and glucose. Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross- povidone, sodium starch glycolate, and mixtures thereof.
Examples of effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate. Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts. Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate. Alternatively, only the acid component of the effervescent couple may be present.
7. Quantities of Nanoparticulate Active Agent,
Surface Stabilizer, and Microparticulate Active Agent
The relative amount of at least one nanoparticulate active agent, one or more surface stabilizers, and at least one microparticulate active agent can vary widely. The optimal amount of the surface stabilizers can depend, for example, upon the particular active agent selected, the hydrophilic lipophilic balance (HLB), melting point, and water solubility of the surface stabilizer, and the surface tension of water solutions of the stabilizer, etc.
The concentration of at least one nanoparticulate active agent can vary from about 99.5% to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined weight of the at least one active agent and at least one surface stabilizer, not including other excipients.
The concentration of at least one surface stabilizer can vary from about 0.5% to about 99.999%, from about 5% to about 99.9%, and from about 10% to about 99.5%, by weight, based on the total combined dry weight of at least one active agent and at least one surface stabilizer, not including other excipients.
The concentration of the microparticulate active agent can vary from about 5% to about 85%, by weight, based on the total combined weight of the nanoparticulate active agent, surface stabilizer, and microparticulate active agent, not including other excipients.
B. Methods of Making Compositions of the Invention In another aspect of the invention there is provided a method of preparing formulations having combined CR and IR characteristics. The method comprises: (1) forming a nanoparticulate composition comprising at least one nanoparticulate active agent to be administered and at least one surface stabilizer; (2) adding at least one microparticulate active agent, which is the same or different from the nanoparticulate active agent of (1), and (3) forming a suitable dosage form of the composition for administration. Pharmaceutically acceptable excipients can also be added to the composition for administration.
1. Methods of Making Nanoparticulate Compositions
Methods of making nanoparticulate compositions, which can comprise mechanical grinding, precipitation, homogenization, or any other suitable size reduction process, are known in the art and are described in, for example, the '684 patent.
Methods of making nanoparticulate compositions are also described in U.S. Patent Nos. 5,518,187 and 5,862,999, both for "Method of Grinding Pharmaceutical Substances;" U.S. Patent No. 5,718,388, for "Continuous Method of Grinding Pharmaceutical Substances;" U.S. Patent No. 5,665,331, for "Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers;" U.S. Patent No. 5,662,883, for "Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers;" U.S. Patent No. 5,560,932, for "Microprecipitation of Nanoparticulate Pharmaceutical Agents;" U.S. Patent No. 5,543,133, for "Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles;" U.S. Patent No. 5,534,270, for "Method of Preparing Stable Drug Nanoparticles;" U.S. Patent No. 5,510,118, for "Process of Preparing Therapeutic Compositions Containing Nanoparticles;" and U.S. Patent No. 5,470,583, for "Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation," all of which are specifically incorporated by reference. a. Milling to obtain Nanoparticulate Active Agent Dispersions
Milling of aqueous active agent dispersions to obtain a nanoparticulate dispersion comprises dispersing at least one active agent in a liquid dispersion medium in which the active agent is poorly soluble. By "poorly soluble" it is meant that the active agent has a solubility in a liquid dispersion medium of less than about 30 mg/ml, preferably less than about 10 mg/ml, and more preferably less than about 1 mg/ml. Such a liquid dispersion medium can be, for example, water, aqueous salt solutions, oils such as safflower oil, and solvents such as ethanol, t-butanol, hexane, and glycol. This is followed by applying mechanical means in the presence of grinding media to reduce the particle size of the active agent to the desired effective average particle size. The active agent particles can be reduced in size in the presence of at least one surface stabilizer. Alternatively, the active agent particles may be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the active agent/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode. The resultant nanoparticulate active agent dispersion can be used directly in formulating a dosage form, or the dispersion can be formulated into a powder followed by dosage formulation.
b. Precipitation to Obtain
Nanoparticulate Active Agent Compositions
Another method of forming the desired nanoparticulate composition is by microprecipitation. This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities. Such a method comprises, for example: (1) dissolving the poorly water-soluble active agent in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer to form a solution; and (3) precipitating the formulation from step (2) using an appropriate non-solvent. The method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means. The resultant nanoparticulate active agent dispersion can be used directly in formulating a dosage form, or the dispersion can be formulated into a powder followed by dosage formulation.
c. Homogenization to Obtain Nanoparticulate Active Agent Compositions
Exemplary homogenization methods of preparing active agent nanoparticulate compositions are described in U.S. Patent No. 5,510,118, for "Process of Preparing Therapeutic Compositions Containing Nanoparticles." Such a method comprises dispersing active agent particles in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of the active agent particles to the desired effective average particle size. The active agent particles can be reduced in size in the presence of at least one surface stabilizer. Alternatively, the active agent particles can be contacted with one or more surface stabilizers either before or after particle size reduction. It is preferred, however, to disperse the active agent particles in the liquid dispersion medium in the presence of the at least one surface stabilizer as an aid to wetting of the active agent particles. Other compounds, such as a diluent, can be added to the active agent/surface stabilizer composition either before, during, or after the size reduction process. Dispersions can be manufactured continuously or in a batch mode. The resultant nanoparticulate active agent dispersion can be used directly in formulating a dosage form, or the dispersion can be formulated into a powder followed by dosage formulation.
2. Dosage Formulation Methods of making oral, injectable, transdermal, aerosol, buccal, topical, ocular, aural, etc. pharmaceutical formulations are known in the art, and such methods can be employed in the present invention.
In one embodiment of the invention, nanoparticulate active agent particles having at least one surface stabilizer adsorbed on to the surface of the particles can be incorporated into a dry powder matrix (e.g., through spray drying, spray granulation, or a related pharmaceutically acceptable drying process), and combined with bulk micronized active agent particles by dry blending or a similar mixing process.
In a second embodiment of the invention, nanoparticulate active agent particles can be incorporated into a dry powder matrix (e.g., through spray drying, spray granulation, or a related pharmaceutically acceptable drying process). Separately, micronized active agent particles can be incorporated into a dry powder matrix using a similar approach, and the resulting matrices can then be combined by dry blending or a similar mixing process. In a third embodiment of the invention, micronized active agent particles can be prepared by dry milling (e.g., jet milling or pin milling).
In a fourth embodiment of the invention, micronized active agent particles can be prepared by wet milling, similar to the approach employed in the preparation of nanoparticulate active agent particles described in the '684 patent. In an fifth embodiment of the invention, micronized active agent particles can be employed as the substrate (or a portion thereof) in a spray granulation, rotogranulation, spray coating, or related pharmaceutical process, upon which nanoparticulate active agent particles can be dispersed or deposited to form an outer layer. This particular approach facilitates the release of nanoparticulate active agent particles from the outer layer of the matrix upon exposure to biological fluids, followed by exposure and subsequent dissolution of micronized active agent particles.
In a sixth embodiment of the invention, micronized active agent particles can be employed as the substrate (or a portion thereof) in a high-shear granulation or related pharmaceutical wet-mixing process, upon which nanoparticulate active agent particles can be applied in the form of a granulating fluid. Upon drying, this particular approach enable nanoparticulate active agent particles and micronized active agent particles to be homogeneously distributed in the resulting solid matrix.
In a seventh embodiment of the invention, nanoparticulate active agent particles and micronized active agent particles can exist in the form of a dry powder or powder blend suitable for incorporation into a solid, rapidly disintegrating or "waterless tablet" matrix, the latter being attained upon compression of the dry powder or powder blend using a tablet press or similar pharmaceutically acceptable compression machine.
Exemplary spray drying, lyophilization, granulation, and tableting methods are described below.
a. Spray Drying of Nanoparticulate Dispersions
Dosage forms of nanoparticulate dispersions can be prepared by drying the nanoparticulate formulation following size reduction. A preferred drying method is spray drying. The spray drying process is used to obtain a nanoparticulate powder following the size reduction process used to transform the active agent into nanoparticulate sized particles.
In an exemplary spray drying process, the nanoparticulate active agent suspension is fed to an atomizer using a peristaltic pump and atomized into a fine spray of droplets. The spray is contacted with hot air in the drying chamber resulting in the evaporation of moisture from the droplets. The resulting spray is passed into a cyclone where the powder is separated and collected. The nanoparticulate dispersion can be spray-dried in the presence or absence of excipients to give the spray-dried intermediate powder.
The powder can be formulated, for example, into a tablet, suppository, or other solid dosage form, or the powder can be formulated into an aerosol for nasal or pulmonary administration. The powder can also be reconstituted into a liquid, and used, for example, for injectable, ocular, ear, or oral dosage forms.
b. Lyophilization
Solid dose forms of nanoparticulate dispersions can also be prepared by lyophilizing the nanoparticulate formulation following size reduction. Suitable lyophilization conditions include, for example, those described in EP 0,363,365 (McNeil-PPC Inc.), U.S. Patent No. 4,178,695 (A. Erbeia), and U.S. Patent No.
5,384,124 (Farmalyoc), all of which are incorporated herein by reference. Typically, the nanoparticulate dispersion is placed in a suitable vessel and frozen to a temperature of between about -5°C to about -100°C. The frozen dispersion is then subjected to reduced pressure for a period of up to about 48 hours. The combination of parameters such as temperature, pressure, dispersion medium, and batch size will impact the time required for the lyophilization process. Under conditions of reduced temperature and pressure, the frozen solvent is removed by sublimation yielding a solid, porous, IR solid dosage form having the active ingredient distributed throughout.
The powder can be formulated, for example, into a tablet, suppository, or other solid dosage form, or the powder can be formulated into an aerosol for nasal or pulmonary administration. The powder can also be reconstituted into a liquid, and used, for example, for injectable, ocular, ear, or oral dosage forms. c. Granulation
Alternatively, a solid oral dosage form of the invention can be prepared by granulating in a fluidized bed an admixture comprising a nanoparticulate dispersion of active agent and at least one surface stabilizer with a solution of at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, to form a granulate. This is followed by tableting of the granulate to form a solid dosage form.
d. Tableting
The dosage formulations of the invention can be in the form of tablets. Preparation of such tablets can be by pharmaceutical compression or molding techniques known in the art. The tablets of the invention may take any appropriate shape, such as discoid, round, oval, oblong, cylindrical, triangular, hexagonal, and the like.
Powders for tableting can be formulated into tablets by any method known in the art. Suitable methods include, but are not limited to, milling, fluid bed granulation, dry granulation, direct compression, spheronization, spray congealing, and spray-dying.
Detailed descriptions of tableting methods are provided in Remington: The Science and
Practice of Pharmacy, 19th ed. Vol. 11 (1995) (Mack Publishing Co., Pennsylvania); and Remington's Pharmaceutical Sciences, Chapter 89, pp. 1633-1658 (Mach Publishing Company, 1990), both of which are specifically incorporated by reference. The tablets may be coated or uncoated. If coated they may be sugar-coated (to cover objectionable tastes or odors and to protect against oxidation) or film coated (a thin film of water soluble matter for similar purposes).
C. Administration of the Compositions of the Invention
The present invention provides a method of treating a mammal, including a human, requiring the rapid availability of at least one poorly soluble active ingredient in combination with controlled release of the same or a different poorly soluble active ingredient. The administered compositions of the invention rapidly release an incorporated active agent resulting in fast onset of activity, and simultaneously slowly release the same or a different active agent for a prolonged pharmacological effect.
In general, the compositions of the invention will be administered to a mammalian subject in need thereof using a level of drug or active agent that is sufficient to provide the desired physiological effect. The mammalian subject may be a domestic animal or pet but preferably is a human subject. The level of drug or active agent needed to give the desired physiological result is readily determined by one of ordinary skill in the art by referring to standard texts, such as Goodman and Gϊllman and the Physician 's Desk Reference .
The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. Throughout the specification, any and all references to a publicly available documents are specifically incorporated into this patent application by reference.
Example 1 The purpose of this example was to simulate, using a mathematical model, pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing an active agent having a single defined particle size.
The software used for the simulation was MicroMath PKAnalyst for Windows, version 1.1, MicroMath, Inc. The following assumptions were made: the active agent conforms to a 2-compartment (central and peripheral compartments) pharmacokinetic model with lst-order absorption and lst-order elimination from the central compartment.
D/V (dose/volume) = 5000;
Ka > 1.000 h"1 (rate constant corresponding to the rate of dissolution);
Ke = 0.50 h"1 (elimination rate constant); Kι2 = 0.25 h"1 (constant representing the rate of diffusion from the central compartment to the peripheral compartment); and
K21 = 0.125 h"1 (constant representing the rate of diffusion from the peripheral compartment to the central compartment).
Four samples were designed, (S) small particles, (MS) medium small particles, (ML) medium large particles, and (L) particles, having the following dissolution rate constants: dissolution rate constant for small (S) particles = 1.000 h"1 dissolution rate constant for medium small (MS) particles = 0.500 h"1 dissolution rate constant for medium large (ML) particles = 0.250 h"1 dissolution rate constant for large (L) particles = 0.125 h"1
The results of the simulation are shown in Figure 1.
The small particle population (S) showed rapid onset of activity, peaking at a plasma concentration level of about 2100 mg/mL at a little over 1 hour following administration, with plasma levels of over 250 mg/mL several minutes following administration. However, this sample also exhibited the lowest plasma levels at 12 hours after administration.
In contrast, the large particle population (L) showed slow onset of activity, peaking at a plasma concentration level of a little over 500 mg/mL at about 2 hours after administration. However, this sample also exhibited the highest plasma levels at 12 hours after administration.
The results of the simulation demonstrate that small particles dissolve faster than larger particles, but that they also decay more rapidly. As a consequence, larger drug particles provide the longest blood plasma levels, although these same particles exhibit slow dissolution.
Example 2
The purpose of this example was to simulate, using a mathematical model, pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing mixtures of different sizes of particles.
The assumptions described in Example 1 are applicable to Example 2. Simulated pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing 50:50 mixtures of small (S) particles plus medium-small (MS), medium-large (ML), or large (L) particles of an active pharmaceutical ingredient are shown in Figure 2.
The results show, in particular, that the mixture of (S) small and (L) large particles exhibits a significantly greater maximum mean plasma concentration (almost 1000 mg/mL) as compared to the (L) large particles administered in Example 1, and the formulation also exhibits prolonged blood plasma levels, in contrast to the to the (S) small particles administered in Example 1. Example 3
The purpose of this example was to simulate, using a mathematical model, pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing mixtures of different sizes of particles. The assumptions described in Example 1 are applicable to Example 3.
Simulated pharmacokinetic profiles following single oral doses of a pharmaceutical formulation containing 25:75 mixtures of small (S) plus medium-small (MS), medium-large (ML), or large (L) particles of an active pharmaceutical ingredient are shown in Figure 3. The results show, in particular, that the mixture of (S) small and (L) large particles exhibits a significantly greater maximum mean plasma concentration (almost 900 mg/mL) as compared to the (L) large particles administered in Example 1, and the formulation also exhibits prolonged blood plasma levels, in contrast to the to the (S) small particles administered in Example 1.
* * * *
It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

Claims

WE CLAIM:
1. A composition comprising:
(a) particles of at least one poorly soluble active agent having an effective average particle size of less than about 1 micron;
(b) at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles; and
(c) at least one micronized active agent, which is either the same as or different from the active agent of (a), and having an effective average particle size of greater than about 1 micron and less than about 100 microns.
2. The composition of claim 1, wherein the effective average particle size of the nanoparticulate active agent particles is selected from the group consisting of less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, and less than about 50 nm.
3. The composition of claim 1 or 2, wherein the effective average particle size of the microparticulate active agent particles is greater than about 1 micron and less than the size selected from the group consisting of less than about 90 microns, less than about 80 microns, less than about 70 microns, less than about 60 microns, less than about 50 microns, less than about 40 microns, less than about 30 microns, less than about 20 microns, less than about 10 microns, less than about 9 microns, less than about 8 microns, less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, less than about 3 microns, and less than about 2 microns.
4. The composition of any of claims 1-3 comprising more than one population of nanoparticulate active agent particles, wherein each population of particles has an effective average particle size which is less than about 1 micron.
5. The composition of any of claims 1-4 comprising more than one population of microparticulate active agent particles, wherein each population of particles has an effective average particle size which is greater than about 1 micron and less than about 100 microns.
6. The composition of any of claims 1-5, wherein the concentration of the nanoparticulate active agent is from about 99.5% to about 0.001%, based upon the total weight of the nanoparticulate active agent and the surface stabilizer.
7. The composition of any of claims 1-6, wherein the concentration of the nanoparticulate active agent is from about 95% to about 0.1% (w/w), based upon the total weight of the nanoparticulate active agent and the surface stabilizer.
8. The composition of any of claims 1-7, wherein the concentration of the nanoparticulate active agent is from about 90% to about 0.5% (w/w), based upon the total weight of the nanoparticulate active agent and the surface stabilizer.
9. The composition of any of claims 1-8, wherein the concentration of the surface stabilizer is from about 0.5% to about 99.999% (w/w), based upon the total weight of the nanoparticulate active agent and the surface stabilizer.
10. The composition of any of claims 1-9, wherein the concentration of the surface stabilizer is from about 5% to about 99.9% (w/w), based upon the total weight of the nanoparticulate active agent and the surface stabilizer.
11. The composition of any of claims 1-10, wherein the concentration of the surface stabilizer is from about 10% to about 99.5% (w/w), based upon the total weight of the nanoparticulate active agent and the surface stabilizer.
12. The composition of any of claims 1-11, wherein the concentration of the microparticulate agent is from about 5% to about 85%, based upon the total weight of the microparticulate active agent, nanoparticulate active agent, and surface stabilizer.
13. The composition of any of claims 1-12 formulated into a solid, rapidly disintegrating, "waterless tablet" matrix.
14. The composition of any of claims 1-12 formulated into a pharmaceutically acceptable tablet.
15. The composition of any of claims 1-12 formulated into a pharmaceutically acceptable hard gelatin capsule.
16. The composition of any of claims 1-12 formulated into a pharmaceutically acceptable soft gelatin capsule.
17. The composition of claim 16, wherein the composition comprises solubilized active agent in place of the nanoparticulate active agent particles.
18. The composition of any of claims 1-12 formulated into a pharmaceutically acceptable lozenge or troche.
19. The composition of any of claims 1-12 formulated into a pharmaceutically acceptable sachet, powder, or "sprinkle".
20. The composition of any of claims 1-19 formulated into a dosage form for oral, rectal, intravaginal, injectable, pulmonary, nasal, buccal, topical, local, intracistemal, intraperitoneal, ocular, aural, buccal spray, or nasal spray administration.
21. The composition of any of claims 1-20, wherein the formulation is made utilizing at least one method selected from the group consisting of spray drying, spray granulation, fluid bed granulation, high shear granulation, fluid bed drying, lyophilization, tableting, jet milling, pin milling, wet milling, rotogranulation, and spray coating.
22. The composition of any of claims 1-21, wherein the nanoparticulate and microparticulate active agents are selected from the group consisting of proteins, peptides, nucleotides, anti-obesity drugs, nutraceuticals, corticosteroids, elastase inhibitors, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio- pharmaceuticals, sex hormones, anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, and xanthines.
23. The composition of any of claims 1-22, wherein the at least one surface stabilizer is selected from the group consisting of a nonionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, and an ionic surface stabilizer.
24. The composition of any of claims 1-23, wherein the at least one surface stabilizer is selected from the group consisting of cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, stearic acid esters and salts, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(l, 1,3,3- tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers, poloxamines, a charged phospholipid, dimyristoyl phophatidyl glycerol, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, triblock copolymers of the structure: -(-PEO)~(-PBO-)~(-PEO-)-, p- isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide; n-decyl β-D- glucopyranoside, n-decyl β-D-maltopyranoside, n-dodecyl β-D-glucopyranoside, n- dodecyl β-D-maltoside, heptanoyl-N-methylglucamide, n-heptyl-β-D-glucopyranoside, n-heptyl β-D-thioglucoside, n-hexyl β-D-glucopyranoside, nonanoyl-N- methylglucamide, n-noyl β-D-glucopyranoside, octanoyl-N-methylglucamide, n-octyl- β-D-glucopyranoside, octyl β-D-thioglucopyranoside, lysozyme, a PEG derivatized phospholipid, PEG derivatized cholesterol, a PEG derivatized cholesterol derivative, PEG derivatized vitamin A, PEG derivatized vitamin E, and random copolymers of vinyl acetate and vinyl pyrrolidone.
25. The composition of any of claims 1-23, wherein the at least one cationic surface stabilizer is selected from the group consisting of a polymer, a biopolymer, a polysaccharide, a cellulosic, an alginate, a nonpolymeric compound, and a phospholipid.
26. The composition of any of claims 1-23, wherein the at least one surface stabilizer is selected from the group consisting of cationic lipids, benzalkonium chloride, sulfonium compounds, phosphonium compounds, quarternary ammonium compounds, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride, coconut trimethyl ammonium bromide, coconut methyl dihydroxyethyl ammonium chloride, coconut methyl dihydroxyethyl ammonium bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride bromide, C12-15dimethyl hydroxyethyl ammonium chloride, C^.^dimethyl hydroxyethyl ammonium chloride bromide, coconut dimethyl hydroxyethyl ammonium chloride, coconut dimethyl hydroxyethyl ammonium bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl dimethyl (ethenoxy)4 ammonium chloride, lauryl dimethyl (ethenoxy)4 ammonium bromide, N-alkyl (C12_ι8)dimethylbenzyl ammonium chloride, N-alkyl (Cι . 18)dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C12_ι4) dimethyl 1-napthylmethyl ammonium chloride, trimethylammonium halide, alkyl- trimethylammonium salts, dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt, an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C1 .ι ) dimethyl 1-naphthylmethyl ammonium chloride, dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, 2 trimethyl ammonium bromides, Cι5 trimethyl ammonium bromides, C1 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride, POLYQUAT 10™, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters, benzalkonium chloride, stearalkonium chloride compounds, cetyl pyridinium bromide, cetyl pyridinium chloride, halide salts of quaternized polyoxyethylalkylamines, MIRAPOL™, ALKAQUAT™, alkyl pyridinium salts; amines, amine salts, amine oxides, imide azolinium salts, protonated quaternary acrylamides, methylated quaternary polymers, cationic guar, polymethylmethacrylate trimethylammonium bromide, polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate, hexadecyltrimethyl ammonium bromide, poly (2- methacryloxyethyltrimethylammonium bromide) (S1001), ρoly(N-vinylpyrrolidone/2- dimethylaminoethyl methacrylate) di methylsulphate quarternary (S1002), and poly(2- methylacryloxyamidopropyltrimethylammonium chloride) (S1004).
27. The composition of any of claims 1-26, comprising two or more surface stabilizers.
28. The composition of any of claims 1-27, comprising sodium lauryl sulfate, dioctyl sodium sulfosuccinate, or a combination thereof, as surface stabilizers.
29. A method of preparing a formulation comprising:
(a) combining (i) particles of at least one nanoparticulate poorly soluble active agent and at least one surface stabilizer adsorbed to the surface thereof, wherein the nanoparticulate active agent has an effective average particle size of less than about 1000 nm, and (ii) at least one microparticulate active agent having an effective average particle size of greater than about 1 micron and less than about 10 microns; and
(b) forming a suitable dosage formulation.
30. The method of claims 29, wherein the microparticulate active agent particles are prepared by dry milling.
31. The method of claim 29 or 30, wherein the microparticulate, nanoparticulate, or both active agent particles are prepared by wet milling.
32. The method of any of claims 29-31 , wherein the nanoparticulate active agent particles having at least one surface stabilizer adsorbed onto the surface of the particles are incorporated into a dry powder matrix by spray drying, spray granulation, lyophilization, or a related pharmaceutically acceptable drying process, and then combined with bulk micronized active agent particles by dry blending or a similar mixing process.
33. The method of any of claim 29-32, wherein:
(a) the nanoparticulate active agent particles having at least one surface stabilizer adsorbed on to the surface of the particles are incorporated into a dry powder matrix by spray drying, spray granulation, lyophilization, or a related pharmaceutically acceptable drying process;
(b) the micronized active agent particles are incorporated into a dry powder matrix by spray drying, spray granulation, lyophilization, or a related pharmaceutically acceptable drying process; and
(c) the resulting matrices from (a) and (b) are combined by dry blending or a similar mixing process.
34. The method of any of claims 29-31, wherein the microparticulate active agent particles are coated with the nanoparticulate active agent/surface stabilizer particles.
35. The method of claim 34, wherein the coating is accomplished by a method selected from the group consisting of spray granulation, rotogranulation, spray coating, or a related pharmaceutical process.
36. The method of any of claims 29-31, wherein the microparticulate active agent particles are employed as a substrate in a high-shear granulation or related pharmaceutical wet-mixing process, upon which nanoparticulate active agent/surface stabilizer particles are applied in the form of a granulating fluid, wherein upon drying the nanoparticulate active agent particles and microparticulate active agent particles are homogeneously distributed in the resulting solid matrix.
37. The method of any of claims 29-36, wherein the nanoparticulate active agent/surface stabilizer particles and microparticulate active agent particles are formulated into a dry powder or powder blend for incorporation into a solid, rapidly disintegrating matrix, followed by compressing the dry powder or powder blend using a tablet press or similar pharmaceutically acceptable compression machine to form tablets.
38. Use of the composition of claim 1 for making a pharmaceutical which is useful in treating a mammal.
PCT/US2002/032314 2001-10-12 2002-10-11 Compositions having a combination of particles for immediate release and for controlled release WO2003030872A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2002334939A AU2002334939A1 (en) 2001-10-12 2002-10-11 Compositions having a combination of particles for immediate release and for controlled release
CA2463495A CA2463495C (en) 2001-10-12 2002-10-11 Compositions having a combination of immediate release and controlled release characteristics
JP2003533905A JP2005508939A (en) 2001-10-12 2002-10-11 Composition having combined immediate release and sustained release characteristics
DK02800993T DK1443912T3 (en) 2001-10-12 2002-10-11 Compositions with a combination of immediate and controlled release properties
EP02800993A EP1443912B1 (en) 2001-10-12 2002-10-11 Compositions having a combination of immediate release and controlled release characteristics
DE60222160T DE60222160T2 (en) 2001-10-12 2002-10-11 COMPOSITIONS COMPRISING PROPERTIES OF IMMEDIATE RELEASE AND CONTROLLED RELEASE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32840501P 2001-10-12 2001-10-12
US60/328,405 2001-10-12

Publications (2)

Publication Number Publication Date
WO2003030872A2 true WO2003030872A2 (en) 2003-04-17
WO2003030872A3 WO2003030872A3 (en) 2003-07-31

Family

ID=23280838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/032314 WO2003030872A2 (en) 2001-10-12 2002-10-11 Compositions having a combination of particles for immediate release and for controlled release

Country Status (12)

Country Link
US (1) US6908626B2 (en)
EP (1) EP1443912B1 (en)
JP (5) JP2005508939A (en)
AT (1) ATE371442T1 (en)
AU (1) AU2002334939A1 (en)
CA (1) CA2463495C (en)
CY (1) CY1107810T1 (en)
DE (1) DE60222160T2 (en)
DK (1) DK1443912T3 (en)
ES (1) ES2292848T3 (en)
PT (1) PT1443912E (en)
WO (1) WO2003030872A2 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1015641A4 (en) * 2003-05-26 2005-07-05 Mariani Jean Paul Micronization 70.
EP1875812A1 (en) * 2005-04-28 2008-01-09 Meiji Seika Kaisha Ltd. Rapidly soluble granule and method for producing the same
EP2032139A2 (en) * 2006-06-23 2009-03-11 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
JP2011105743A (en) * 2003-07-31 2011-06-02 Delavau Llc Calcium carbonate granule
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US9138410B2 (en) 2003-02-21 2015-09-22 Shin Nippon Biomedical Laboratories, Ltd. Compositions for nasal administration of pharmaceuticals
WO2016026822A1 (en) * 2014-08-18 2016-02-25 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US9757464B2 (en) 2009-03-05 2017-09-12 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US10047072B2 (en) 2013-09-16 2018-08-14 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
CN108904506A (en) * 2018-07-27 2018-11-30 河南大华生物技术有限公司 A kind of diclazuril nanometer powder and preparation method thereof
US10195139B2 (en) 2006-12-26 2019-02-05 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
EP2968070B1 (en) 2013-03-15 2019-12-18 Glanbia Nutritionals (Ireland) Ltd. Method for improving bioavailability of therapeutic compounds
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
RU2817019C2 (en) * 2014-08-18 2024-04-09 Алкермес Фарма Айэленд Лимитед Aripiprazole prodrug compositions

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US8551526B2 (en) * 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
ATE464880T1 (en) * 2002-02-04 2010-05-15 Elan Pharma Int Ltd MEDICINAL NANOPARTICLES WITH LYSOZYME SURFACE STABILIZER
US7803402B2 (en) * 2002-07-06 2010-09-28 Sanjeev Khandelwal Pharmaceutical preparations
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
DE10253623B4 (en) * 2002-11-15 2006-03-09 Justus-Liebig-Universität Giessen Biodegradable colloidal particles, especially for pulmonary applications
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20050058702A1 (en) * 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
CA2543458A1 (en) * 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
LT1729739T (en) * 2004-03-29 2016-11-10 Les Laboratoires Servier Process for preparing a solid pharmaceutical composition
US20050214383A1 (en) * 2004-03-29 2005-09-29 William Bubnis Multi-vitamin and mineral nutritional supplements
US20070178151A1 (en) * 2004-03-30 2007-08-02 Vlasios Andronis Spray dried pharmaceutical compositions
US7908041B2 (en) * 2004-04-29 2011-03-15 Munro & Associates, Inc. Self-leveling laser horizon for navigation guidance
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
SI21800A (en) * 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril
US20060165769A1 (en) * 2004-09-30 2006-07-27 Hyatt John A Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
US8246976B2 (en) * 2004-10-08 2012-08-21 Noven Pharmaceuticals, Inc. Transdermal delivery of drugs based on crystal size
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (en) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Nanoparticulate raloxifene hydrochloride composition
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
PT2730277T (en) 2004-12-22 2020-04-21 Nitto Denko Corp Drug carrier and drug carrier kit for inhibiting fibrosis
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
AU2012201630B8 (en) * 2004-12-31 2014-03-06 Iceutica Pty Ltd NanoParticle Composition(s) and Method for Synthesis Thereof
WO2006074218A2 (en) * 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
US20060198896A1 (en) * 2005-02-15 2006-09-07 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Nanoparticulate compositions of heterocyclic amide derivatives
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20090110633A1 (en) * 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
JP2008533174A (en) * 2005-03-16 2008-08-21 エラン ファーマ インターナショナル リミテッド Nanoparticulate leukotriene receptor antagonist / corticosteroid preparation
NZ561666A (en) * 2005-03-17 2010-05-28 Elan Pharma Int Ltd Nanoparticulate biphosphonate compositions
BRPI0609700A2 (en) * 2005-03-23 2010-04-20 Elan Pharma Int Ltd nanoparticulate corticosteroid and antihistamine formulations
MX2007012778A (en) * 2005-04-12 2008-01-11 Elan Pharma Int Ltd Nanoparticulate quinazoline derivative formulations.
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
EP1885335A1 (en) * 2005-04-27 2008-02-13 BAXTER INTERNATIONAL INC. (a Delaware corporation) Surface-modified microparticles and methods of forming and using the same
EP1896610A2 (en) * 2005-05-03 2008-03-12 Handylab, Inc. Lyophilized pellets
WO2006117220A2 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
JP2008540546A (en) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド Nanoparticulate clopidogrel formulation
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
US20060275372A1 (en) * 2005-06-03 2006-12-07 Elan Pharma International Limited Nanoparticulate imatinib mesylate formulations
WO2007053197A2 (en) * 2005-06-03 2007-05-10 Elan Pharma International, Limited Nanoparticulate acetaminophen formulations
DE112006001606T5 (en) 2005-06-08 2009-07-09 Elan Pharma International Ltd., Athlone Nanoparticulate and controlled release composition comprising cefditoren
ATE446742T1 (en) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd NANOPARTICULAR EBASTIN FORMULATIONS
KR20080016952A (en) * 2005-06-13 2008-02-22 엘란 파마 인터내셔널 리미티드 Nanoparticulate clopidogrel and aspirin combination formulations
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
EP1904041A2 (en) * 2005-07-07 2008-04-02 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
JP5694643B2 (en) * 2005-08-05 2015-04-01 スリーエム イノベイティブ プロパティズ カンパニー Composition exhibiting improved fluidity
WO2007033239A2 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US20100273844A1 (en) * 2005-09-28 2010-10-28 Oxford Pharmaceutical Services Inc. Pharmaceutical compositions for treating or preventing migaines
EP1942872A2 (en) * 2005-11-04 2008-07-16 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8532938B2 (en) 2005-11-17 2013-09-10 The Invention Science Fund I, Llc Testing-dependent administration of a nutraceutical
US20070112592A1 (en) * 2005-11-17 2007-05-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Payments in providing assistance related to health
US10042980B2 (en) * 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20080082272A1 (en) * 2005-11-30 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US20070299693A1 (en) * 2006-06-23 2007-12-27 Searete Llc, A Limited Liability Corporation Customized visual marking for medication labeling
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
EP2018875A1 (en) 2006-05-15 2009-01-28 Ebara Corporation Poorly-water-soluble pharmaceutical agent
BRPI0712130A2 (en) * 2006-05-30 2012-01-17 Elan Pharma Int Ltd nanoparticulate posaconazole formulations
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
US20070299695A1 (en) * 2006-06-23 2007-12-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Customized visual marking for medication labeling
US20080086339A1 (en) * 2006-06-23 2008-04-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Customized visual marking for medication labeling
US20080086338A1 (en) * 2006-06-23 2008-04-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Customized visual marking for medication labeling
AU2007264418B2 (en) 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
ZA200810741B (en) * 2006-06-30 2010-05-26 Iceutica Ltd Methodes for the preparation of biologically active compounds in nanoparticulate form
TW200820991A (en) * 2006-07-10 2008-05-16 Elan Pharma Int Ltd Nanoparticulate sorafenib formulations
KR20090031618A (en) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 Nanoparticulate formulations of modafinil
CA2655682A1 (en) 2006-08-03 2008-02-07 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
EP2647712A3 (en) * 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
AU2007319577A1 (en) * 2006-10-06 2008-05-22 Baxter Healthcare S.A. Microencapsules containing surface-modified microparticles and methods of forming and using the same
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
WO2008062475A2 (en) * 2006-10-26 2008-05-29 Cadila Healthcare Limited Pharmaceutical compositions of ursodiol
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
US9456983B1 (en) * 2006-12-08 2016-10-04 Advanced Cardiovascular Systems, Inc. Therapeutic composition with enhanced vessel targeting
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
EP2144599B1 (en) 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
TWI407971B (en) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2008137960A1 (en) * 2007-05-07 2008-11-13 Questor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
TW200904340A (en) * 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
JP2010539245A (en) 2007-09-14 2010-12-16 日東電工株式会社 Drug carrier
WO2009108407A1 (en) * 2008-02-25 2009-09-03 The University Of North Carolina At Charlotte Office Of Technology Transfer Biodegradable therapeutic nanoparticles containing an antimicrobial agent
CN107080734B (en) 2008-03-20 2020-10-30 维尔恩公司 Emulsions comprising PEG derivatives of tocopherols
JP2011520779A (en) * 2008-03-21 2011-07-21 エラン・ファルマ・インターナショナル・リミテッド Compositions and methods of use for site-specific delivery of imatinib
US8895546B2 (en) 2009-03-27 2014-11-25 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
ES2586032T3 (en) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2010008475A2 (en) * 2008-06-23 2010-01-21 Virun, Inc. Compositions containing nono-polar compounds
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
JP6027890B2 (en) 2009-04-24 2016-11-16 イシューティカ ピーティーワイ リミテッド New formulation of indomethacin
CN106420667A (en) 2009-04-24 2017-02-22 伊休蒂卡有限公司 A novel formulation of diclofenac
JP6072539B2 (en) 2009-05-27 2017-02-01 アルカーメス ファーマ アイルランド リミテッド Reduction of flaky aggregation in nanoparticulate active agent compositions
US20110021825A1 (en) * 2009-07-21 2011-01-27 Ge Healthcare As Process for isolating iodixanol from an aqueous solution
CN103037708B (en) 2010-03-23 2015-05-20 维尔恩公司 Nanoemulsion including sucrose fatty acid ester
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
FR2960775A1 (en) * 2010-06-07 2011-12-09 Ethypharm Sa MICROGRANULES RESISTANT TO MISMATCH
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
RU2016125229A (en) 2010-07-09 2018-12-04 БиЭйчВи ФАРМА, ИНК. COMBINED DELIVERY SYSTEM WITH IMMEDIATE / SLOW-DELIVERY FOR MEDICINES WITH A SHORT HALF-HOUR, INCLUDING REMOGLYPHLOSIN
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
BR112015009839A2 (en) * 2012-11-01 2017-07-11 Torrent Pharmaceuticals Ltd tapentadol pharmaceutical composition for parenteral administration
JP6251667B2 (en) 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 Tablet-type immediate release preparation and method for producing the same
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN107249567B (en) 2014-11-21 2021-08-03 拜尔哈文制药股份有限公司 Sublingual administration of riluzole
EA036155B1 (en) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Injectable neurosteroid formulations containing nanoparticles
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
SG11201809669RA (en) 2016-05-20 2018-11-29 Biohaven Pharm Holding Co Ltd Use of glutamate modulating agents with immunotherapies to treat cancer
BR112019002538A2 (en) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. use of a pharmaceutical composition comprising an allosteric modulator, use of a pharmaceutical composition comprising garboxadol or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for parenteral administration
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
BR112019013503A2 (en) 2016-12-31 2020-01-07 Bioxcel Therapeutics, Inc. USE OF SUBLINGUAL DEXMEDETOMIDINE TO TREAT AGITATION
SG11202004332XA (en) 2017-11-12 2020-06-29 Biohaven Pharm Holding Co Ltd Use of riluzole prodrugs to treat ataxias
AU2019295699A1 (en) 2018-06-27 2021-01-28 Arx, Llc Film formulations containing dexmedetomidine and methods of producing them
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
MX2022000709A (en) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Non-sedating dexmedetomidine treatment regimens.
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
MX2022006014A (en) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolone for use in treating tuberous sclerosis complex.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352190A1 (en) * 1988-07-21 1990-01-24 Farmalyoc Solid and unitary form containing microparticules and/or nanoparticules, and its preparation
WO1999018934A1 (en) * 1997-10-09 1999-04-22 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
WO2000012124A1 (en) * 1998-09-01 2000-03-09 Elan Corporation, Plc Oral vaccine compositions
WO2000069986A1 (en) * 1999-05-19 2000-11-23 Sarnoff Corporation Method of coating micrometer sized inorganic particles
WO2001013120A1 (en) * 1999-08-17 2001-02-22 Luminex Corporation Microparticles with multiple fluorescent signals and methods of using same
WO2001045706A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Dual-release compositions of a cyclooxygenase-2- inhibitor
WO2002045575A2 (en) * 2000-10-25 2002-06-13 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403078A1 (en) 1977-09-19 1979-04-13 Lafon Labor NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS
FR2561916B1 (en) 1984-03-30 1987-12-11 Lafon Labor GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2685635B1 (en) * 1991-12-27 1995-06-30 Lvmh Rech COMPLEX SOLID PARTICLES COMPRISING A BIOLOGICALLY ACTIVE SOLID SUBSTANCE, THEIR METHOD OF PREPARATION AND TOPICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF BIOLOGICAL SURFACES.
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5110605A (en) 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
GB2257707B (en) * 1991-05-27 1995-11-01 Nippon Zeon Co Adhesive composition
EP0593627A1 (en) 1991-07-05 1994-04-27 The University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5610294A (en) 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
DE4203932A1 (en) 1992-02-11 1993-08-12 Deutsche Aerospace SEND / RECEIVE MODULE
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5264610A (en) 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5631553A (en) * 1993-05-31 1997-05-20 Universite Du Quebec A Trois-Rivieres High precision RF vector analysis system based on synchronous sampling
EP0804170B1 (en) 1993-07-09 2001-11-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5567172A (en) * 1994-09-26 1996-10-22 Aer Energy Resources, Inc. Universal strain relief device for connectors
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
DE4440337A1 (en) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
EP0810853B1 (en) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6177103B1 (en) * 1998-06-19 2001-01-23 Rtp Pharma, Inc. Processes to generate submicron particles of water-insoluble compounds
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2001008299A1 (en) * 1999-07-23 2001-02-01 Fujitsu Limited Low-voltage current mirror circuit
PT1175220E (en) * 1999-12-08 2005-07-29 Pharmacia Corp EPLERENONE COMPOSITIONS IN NANOPARTICLES
ES2236007T3 (en) * 1999-12-08 2005-07-16 Pharmacia Corporation CYCLLOXYGENASA-2 EU INHIBITOR COMPOSITIONS HAS A FAST THERAPEUTIC EFFECT.
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352190A1 (en) * 1988-07-21 1990-01-24 Farmalyoc Solid and unitary form containing microparticules and/or nanoparticules, and its preparation
WO1999018934A1 (en) * 1997-10-09 1999-04-22 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
WO2000012124A1 (en) * 1998-09-01 2000-03-09 Elan Corporation, Plc Oral vaccine compositions
WO2000069986A1 (en) * 1999-05-19 2000-11-23 Sarnoff Corporation Method of coating micrometer sized inorganic particles
WO2001013120A1 (en) * 1999-08-17 2001-02-22 Luminex Corporation Microparticles with multiple fluorescent signals and methods of using same
WO2001045706A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Dual-release compositions of a cyclooxygenase-2- inhibitor
WO2002045575A2 (en) * 2000-10-25 2002-06-13 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138410B2 (en) 2003-02-21 2015-09-22 Shin Nippon Biomedical Laboratories, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
BE1015641A4 (en) * 2003-05-26 2005-07-05 Mariani Jean Paul Micronization 70.
JP2011105743A (en) * 2003-07-31 2011-06-02 Delavau Llc Calcium carbonate granule
EP1875812A4 (en) * 2005-04-28 2009-08-05 Meiji Seika Kaisha Rapidly soluble granule and method for producing the same
EP1875812A1 (en) * 2005-04-28 2008-01-09 Meiji Seika Kaisha Ltd. Rapidly soluble granule and method for producing the same
EP2032139A4 (en) * 2006-06-23 2012-08-22 Elan Pharma Int Ltd Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP2032139A2 (en) * 2006-06-23 2009-03-11 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US10195139B2 (en) 2006-12-26 2019-02-05 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
US9757464B2 (en) 2009-03-05 2017-09-12 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
EP2968070B1 (en) 2013-03-15 2019-12-18 Glanbia Nutritionals (Ireland) Ltd. Method for improving bioavailability of therapeutic compounds
US10047072B2 (en) 2013-09-16 2018-08-14 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
US10577351B2 (en) 2013-09-16 2020-03-03 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
WO2016026822A1 (en) * 2014-08-18 2016-02-25 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
CN106794251A (en) * 2014-08-18 2017-05-31 阿尔科姆斯制药爱尔兰有限公司 Aripiprazole pro-drug composition
EP3182958B1 (en) 2014-08-18 2019-02-27 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
EP3508196A1 (en) * 2014-08-18 2019-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
RU2705376C2 (en) * 2014-08-18 2019-11-07 Алкермес Фарма Айэленд Лимитед Aripiprazole prodrug compositions
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US10688091B2 (en) 2014-08-18 2020-06-23 Alkermes Pharma Ireland Limited Aripiprazole prodrug composition
US10849894B2 (en) 2014-08-18 2020-12-01 Alkermes Pharma Ireland Limited Aripiprazole prodrug composition
CN106794251B (en) * 2014-08-18 2020-12-29 阿尔科姆斯制药爱尔兰有限公司 Aripiprazole prodrug compositions
US11154552B2 (en) 2014-08-18 2021-10-26 Alkermes Pharma Ireland Limited Aripiprazole prodrug composition
RU2817019C2 (en) * 2014-08-18 2024-04-09 Алкермес Фарма Айэленд Лимитед Aripiprazole prodrug compositions
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN108904506A (en) * 2018-07-27 2018-11-30 河南大华生物技术有限公司 A kind of diclazuril nanometer powder and preparation method thereof

Also Published As

Publication number Publication date
US20030137067A1 (en) 2003-07-24
DE60222160T2 (en) 2008-06-12
EP1443912A2 (en) 2004-08-11
JP2005508939A (en) 2005-04-07
EP1443912B1 (en) 2007-08-29
CA2463495C (en) 2011-05-24
JP2015108022A (en) 2015-06-11
JP2017075182A (en) 2017-04-20
ATE371442T1 (en) 2007-09-15
AU2002334939A1 (en) 2003-04-22
CA2463495A1 (en) 2003-04-17
JP2013209422A (en) 2013-10-10
US6908626B2 (en) 2005-06-21
CY1107810T1 (en) 2013-06-19
JP2010047599A (en) 2010-03-04
ES2292848T3 (en) 2008-03-16
WO2003030872A3 (en) 2003-07-31
DE60222160D1 (en) 2007-10-11
DK1443912T3 (en) 2008-01-21
PT1443912E (en) 2007-11-28

Similar Documents

Publication Publication Date Title
US6908626B2 (en) Compositions having a combination of immediate release and controlled release characteristics
EP1585502B9 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
CA2479735C (en) Fast dissolving dosage forms having reduced friability
US8236352B2 (en) Glipizide compositions
US7842232B2 (en) Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US20040105778A1 (en) Gamma irradiation of solid nanoparticulate active agents
US20040115134A1 (en) Novel nifedipine compositions
US20070098805A1 (en) Methods of making and using novel griseofulvin compositions
WO2007053197A2 (en) Nanoparticulate acetaminophen formulations
WO2008008733A2 (en) Nanoparticulate sorafenib formulations
EP1968548A2 (en) Mometasone compositions and methods of making and using the same
US20090291142A1 (en) Nanoparticulate bicalutamide formulations
WO2006138421A2 (en) Nanoparticulate azelnidipine formulations
US20090104273A1 (en) Novel nifedipine compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003533905

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2463495

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002800993

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002800993

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002800993

Country of ref document: EP